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2 Abstract 
Background: Diabetes is characterized by impaired glucose stimulated insulin secretion (GSIS) from the 
pancreatic -cells. The pyruvate dehydrogenase complex (PDC) catalyzes the irreversible decarboxylation of 
pyruvate to acetyl-CoA in the breakdown of glucose. The catabolism of glucose drives the formation of ATP, 
which triggers GSIS. It is shown that mir-29a is up-regulated in several tissues in response to hyperglycemia 
and that over-expression of miR-29a impairs GSIS, while depletion improves GSIS. Based on a target 
sequence analysis it was hypothesized that the 3’UTR of the E3 binding protein mRNA, a subunit of PDC, 
could be a potential target for binding of miR-29a. The expression of miR-29a would thus down-regulate 
the function of the entire complex. 
Methods: To investigate whether the 3’UTR of PDHx is a target of miR-29a a reporter gene analysis was 
conducted. A vector construct containing PDHx 3’UTR was transfected into rat insulinoma pancreatic β-cell 
lines (INS-1E), one of which was over-expressing miR-29a (miR-29a OE), while the other expressed a 
microRNA with no targets (NTC). The controls compared to PDHxUTR were miR-29a perfect, miR-29a 
mutated and Syntaxin-1a. A vector construct of a mutated PDHxUTR was designed in order to compare with 
the wild type PDHxUTR, the mutagenesis was however unsuccessful. The reporter vectors were co-
transfected with a normalization vector expressing β-galactosidase or renilla luciferase. Additionally the 
reporter gene analysis was conducted in a transient miR-29a mimic system where INS-1E cells were 
transfected with the same set of vectors but with positive and negative mimics of miR-29a added to the 
cells instead of the constitutive endogenous expression.  
Results: An overlap-extension PCR and a whole plasmid PCR were employed in the mutagenesis of 
PDHxUTR. The mutagenesis was not successful, and the reporter gene analysis was therefore only 
performed for the wild type pMirTarget PDHxUTR. Transfections using the endogenous constitutive 
expression of miR-29a showed a significant decrease in normalizations factors β-galactosidase and RR 
luciferase activities between the NTC and miR-29a OE cell line for all reporter vectors. When lowering the 
concentration of normalization vector, the β-galactosidase activities became more similar between the 
cells. The protein concentrations differed significantly between the cell lines in the first transfections, 
indicating a different growth rate for the two cell lines. In the mimic system PDHxUTR showed a lower 
reporter gene activity when treated with positive mimic. Additionally, the controls yielded the expected 
results. 
Conclusion: Transfections using mimic oligos were superior to the endogenous constitutive transfections. 
The results indicate a binding of miR-29a to a target site in PDHxUTR. As the experiment was only 
performed once the results are non-conclusive, but it is advised that replicates are performed including the 
mutation of PDHxUTR to confirm the regulatory effect of miR-29a on PDHx. 
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4 Introduction 
This project investigates the regulatory effect of microRNA-29a (miR-29a) on a possible target mRNA 
encoding the dihydrolipoyl dehydrogenase (E3) binding protein subunit of the pyruvate dehydrogenase 
complex (PDC). Since PDC is a key enzyme in the conversion of sugar to energy and the maintenance of 
blood glucose homeostasis it is noteworthy that increased levels of miR-29a has been observed in type 2 
diabetes (He et al., 2007; Herrera et al., 2010). One of the mechanisms that define diabetes is the loss of 
the ability to regulate blood glucose levels. The dysregulation occurs partially due to impairment of glucose 
stimulated insulin secretion (GSIS) of the pancreatic β-cells. Normally, high blood glucose levels trigger the 
secretion of insulin which in turn promotes the catabolism of glucose. One of the premises of successful β-
cell function is the correct breakdown of glucose through glycolysis and the subsequent entry of acetyl -CoA 
into the tricarboxylic acid (TCA) cycle (Srinivasan et al., 2010). A control of PDC activity is therefore crucial 
for glucose homeostasis and the production of ATP (Harris et al., 2002). 
Insulin is secreted from the Islets of Langerhans in pancreatic β-cells. Metabolism of glucose in β-cells and 
increase of intracellular and cytosolic ATP is essential for insulin to be secreted. Glucose enters the β-cells 
through the glucose transporter, GLUT2, from where it is converted to pyruvate in glycolysis. PDC 
subsequently converts pyruvate to acetyl-CoA, which is the substrate for the TCA cycle that occurs in the 
mitochondrial matrix and generates reducing agents needed for ATP production via the respiratory chain. 
Pancreatic β-cells contain ATP-sensitive K+ channels (KATP channels) on the surface and when cytoplasmic 
ATP levels are elevated, the KATP channels close and cause membrane depolarization. Voltage gated Ca
2+ 
channels open and influx of calcium to the cytoplasm stimulates insulin secretion by exocytosis (Figure 1) 
(Komatsu et al., 2013; Srinivasan et al., 2010)  
 
Figure 1 Glucose stimulated insulin secretion Glucose is taken up by the glucose transporter, GLUT-2, in the plasma membrane of 
the pancreatic -cells and is metabolized through glycolysis to pyruvate in the mitochondria. ATP levels increase and cause the ATP-
sensitive K+ channels to close and depolarize the inner membrane of the -cells. The depolarization of the membrane causes  the 
ca lcium channels to open and the influx of Ca + s timulates the insulin-containing vesicles to secrete insul in by exocytos is . (Singh, 
2012) 
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If the mRNA of PDHx, a gene encoding a subunit for PDC, contains a target site for miR-29a, glycolysis will 
be impaired when miR-29a levels are high, which will results in reduced ATP generation and finally, less 
insulin will be secreted due to lower ATP levels.  
 
MiRNAs bind primarily to the 3’ untranslated region (UTR) in the mRNA of the genes they regulate, down-
regulating the translation by either breakdown of the mRNA or by making it inaccessible to the ribosomes 
(Bartel, 2004; Rana, 2007). It has been found that miR-29a levels are increased in muscle, fat and liver in 
diabetic animals and mediate decreased insulin-stimulated glucose-transport of adipocytes (He et al., 2007; 
Pandey et al., 2011). Based on this discovery and a target analysis of miR-29a, it is hypothesized that the 
3’UTR of PDHx (PDHxUTR) is a target sequence for miR-29a (MicroRNA.org, 2010; TargetScan.org, 2012) 
and that the entire complex is downregulated when miR-29a is bound to PDHxUTR.   
 
4.1 Aim  
The aim of this project was to investigate whether PDHxUTR is a target of miR-29a. This was intended to be 
investigated by producing a firefly (FF) luciferase reporter vector construct incorporating a wild type PDHx 
3’UTR and a mutated version of PDHxUTR with an altered expected binding site for miR-29a. The vectors 
were transfected into rat pancreatic β-cell lines (INS-1E) in order to quantify luciferase activity in response 
to normal levels and over-expressed levels of miR-29a in. The expression of the reporter gene is designed 
to be dependent on PDHx translation. If indeed miR-29a down-regulates the expression of PDHx, the results 
from this experimental setup will show lowered levels of FF luciferase when transfecting miR-29a 
overexpressing cells with the PDHxUTR reporter vector, compared to the included controls. 
 
4.2 Focus 
In order to understand PDHx regulation, the whole pyruvate dehydrogenase complex is explained, including 
components, cofactors and functions. We will focus on the eukaryotic PDC, how it is regulated and its 
functions. A general description of miRNAs is provided along with their biogenesis. Further, in o rder to 
understand the metabolic role of miR-29a, the current literature on the miR-29 family and their targets is 
reviewed in relation to effects on glucose, insulin levels and β-cell function. Other roles of miR-29a in 
pathogenesis such as its relation to oncogenes and fibrosis are not investigated. The mechanisms occurring 
in type 2 diabetes mellitus will be reflected upon when looking into the functions of pancreatic β-cells, but 
the disease is not described in detail . 
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5 The pyruvate dehydrogenase complex 
The mitochondrial PDC converts pyruvate to acetyl-CoA by an irreversible oxidative decarboxylation. 
Pyruvate is the end product of glycolysis and the reaction thus links glycolysis with the TCA cycle and 
constitutes a major role in the conversion of carbohydrates into energy (Figure 2). Since the conversion of 
pyruvate into acetyl-CoA is irreversible, a tight regulation of PDC activity is crucial for both glucose 
homeostasis, ATP production and for the facilitation of fatty acid oxidation when glucose is scarce (Patel 
and Korotchkina, 2003).  
 
Figure 2 The role of PDC. PDC is  a  three subunit enzyme which catalyzes the irreversible convers ion of pyruvate to acetyl -CoA by 
the reduction of NAD
+
 to NADH. Pyruvate is supplied by the glycolysis of glucose. Another fate of pyruvate i s  the fermentation to 
lactate. Acetyl-CoA is the substrate for the TCA cycle and synthesis of fatty acids  and amino acids . PDC is  activated by PDP and 
inactivated by PDK. PDC: pyruvate dehydrogenase complex. PDP: pyruvate dehydrogenase phosphatase, PDK: pyr uvate 
dehydrogenase kinase TCA: tricarboxyl ic acid.  
 
The PDC is a member of the α-keto acid dehydrogenase complex family (Patel and Roche, 1990) and is 
located in the mitochondrial matrix in eukaryotes (Nelson et al., 2008). PDC consists of three catalytic 
components; pyruvate dehydrogenase (E1), dihydrolipoyl acyltransferase (E2) and E3 (Figure 3), all of which 
perform the major catalytic labor while PDH kinase (PDK) and PDH phosphatase (PDP) are negative and 
positive regulators of PDC activity, respectively. Additionally, there is a smaller non-catalytic component, 
E3-binding protein (E3BP), formerly known as protein X, which maintains a structural role by binding 
component E2 to E3 (Hiromasa et al., 2004; Patel and Korotchkina, 2003). The process of converting 
pyruvate to acetyl-CoA occurs via substrate channeling and begins with the E1 component catalyzing the 
decarboxylation of pyruvate into and the conversion of thiamine pyrophosphate (TPP) to hydroxyethyl-TPP, 
followed by reductive acetylation of lipoyl groups covalently attached to  E2 lipoyl domains. The E2 
component catalyzes the formation of acetyl-CoA by transfer of acetyl groups from the reduced lipoyl 
group to CoA (Harris et al., 2001). The E3 component then reoxidizes the reduced lipoyl moieties of E2 with 
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the consequent reduction of NAD+ to NADH (Neagle et al., 1989; Patel and Roche, 1990). The components 
of the PDC are summarized in Table 1.  
 
Figure 3 The catalytic activities of pyruvate in the pyruvate dehydrogenase complex. The complex cons is ts  of components ; 
pyruvate dehydrogenase (E1), dihydrolipoyl acetyl transferase (E2) and dihydrol ipoyl  dehydrogenase (E3). ① E1 cata lyzes  the 
decarboxylation of pyruvate to hydroxyethyl-TPP. ② Reductive acetylation of l ipoyl  groups  covalen tly attached to E2 l ipoyl  
domains. ③ E2 catalyzes the formation of acetyl-CoA by transfer of acetyl groups. ④ E3 reoxidizes the reduced lipoyl moieties  of 
E2.  ⑤ The reoxidization is accompagnied by reduction of NAD + to NADH. TPP: thiamine pyrophosphate (Nelson et a l ., 2008). 
 
Table 1 Components of the eukaryotic PDC based on s tudies  of yeast PDC.  (Brautigam et a l ., 2006)  
Components Name No. of components in PDC Cofactors 
E1 Pyruvate dehydrogenase 30 TPP 
E2 Dihydrolipoyl acetyltransferase 60 Lipoate, Coenzyme A 
E3 Dihydrolipoyl dehydrogenase 12 NAD
+
, FAD
 
E3BP E3 binding protein 12* Lipoate 
*(Hiromasa et al., 2004) proposes a  E2/E3BP ratio of 48/12 based on a  study of bovine PDC. The reason for s tructura l  di fferences  
between yeast and bovine PDC is  yet unknown. 
 
5.1 The E3BP component 
Mammalian E3BP contains a lipoyl group, a subunit-binding domain and an inner domain, all of which are 
linked by hinge regions. It is structurally similar to the E2 component (Figure 4). A comparison of the amino 
acids sequences of human E3BP and human E2, shows one difference in that E3BP has one  putative lipoyl-
bearing domain in its amino-terminal region rather than two tandemly repeated lipoyl-bearing domains 
present in E2 (Harris et al., 1997). E3BP is important in conserving the structure of the PDC. It is shown to 
be tightly bound to subunit E2 by its inner domain and further binds subunit E3 (Aral et al., 1997; Hiromasa 
et al., 2004).  
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Figure 4 The structure of mammalian E2 and E3BP. The Inner domain of E3BP (I’) i s at the C-terminal and is the site where it binds  
to the I domain of E2. The lipoyl domains (L1-L3) are at the N-terminal and the subunit binding domains (B and B’) are the ones that 
bind to other subunits; B of E2 binds to E1 and B’ of E3BP binds to E3. H1-3 and H1’-H2’ are hinge regions (Hiromasa et a l ., 2004). 
 
In humans, E3BP is encoded by PDHx and located on chromosome 11  (Aral et al., 1997; NCBI, 2014). The 
E3BP is present in eukaryotes but is lacking in prokaryotes (Patel and Korotchkina, 2003; Patel and Roche, 
1990). The role of E3BP in binding subunit E2 and E3 was demonstrated by removal of a NH2-terminal lipoyl 
domain of E3BP, which greatly reduced binding of the E3 component to the E2 subunit and thus lowered 
the activity of the PDC (Powers-Greenwood et al., 1989). Lawson et al. (1991) showed that isolation of PDC 
from cells with a mutated PDHx lacked E3BP and E3 and resulted in a non-functional PDC. Additionally by 
deletion of the subunit-binding domain of E3BP, this region was found to bind E3, due to a lack of E3-
binding and PDC activity. These results thus confirm the critical role of E3BP in binding E3 (Lawson et al., 
1991).  
 
5.2 PDC deficiency 
PDC deficiency is primarily related to lactic acidosis and neurological dysfunction in infancy and childhood 
(Brown et al., 1994). The brain requires aerobic oxidation of glucose for energy supply and because PDC is 
essential for this process, patients with PDC deficiency usually have neurological dysfunction. Lactic acidosis 
is often fatal in newborn children and occurs when the PDC does not convert pyruvate into acetyl -CoA. 
Instead, pyruvate is fermented anaerobically to lactic acid which causes a decrease in pH in tissues and 
blood (Brown et al., 1994, 2006). PDC deficiency is most commonly caused by mutations in the X-
chromosome linked gene PDHA, which encodes the E1α subunit. However, mutations in PDHx have also 
been observed and these result in a lack of E3BP synthesis which in turn leads to impaired PDC assembly 
(Aral et al., 1997; Brown et al., 2006; Tajir et al., 2012).  
Inhibition of PDC activity impairs the mitochondrial oxidation of pyruvate and promotes its reduction to 
lactate. A lower flux through the complex also decreases the availability of acetyl -CoA for the TCA cycle. A 
reduction in the activity of both PDC and the TCA cycle decreases the generation of reducing equivalents 
(NADH and FADH2), which donate electrons to the respiratory chain (Patel et al., 2012).  
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5.3 Regulation of the pyruvate dehydrogenase complex  
The rate of pyruvate decarboxylation must be controlled carefully to match energy needs in different 
tissues, which changes during different nutritional and hormonal stages. When glucose is scarce, 
mechanisms exist to inactivate PDC. PDC never exists in its completely active or inactive state and the 
relative activities of protein kinases and phosphatases determine the activity. Meals rich in carbohydrates 
and low in fat provoke a maximum flux through PDC to increase the catabolism of glucose and to increase 
the synthesis of fatty acids from the TCA cycle. On the contrary, during prolonged fasting or consuming 
meals rich in fat, PDC is inactivated in a larger extent to minimize loss of pyruvate and decrease the 
synthesis of fatty acids (Harris et al., 2002). 
Acetyl-CoA and NADH, which are the products of the PDC reaction, exert feedback inhibition of PDC, when 
their concentrations are sufficiently elevated in the mitochondrial matrix space.  An elevated ratio of NADH 
to NAD+ and acetyl-CoA to CoA induces PDK to inhibit the activity of PDC. This produces a short-term 
inactivation of PDC activity. Conversely, the substrates of the PDC reaction; pyruvate, NAD+ and CoA, induce 
short-term activation of the complex by inhibition of PDK. (Harris et al., 2002; Ravindran et al., 1996; Yang 
et al., 1998) 
 
PDKs inactivate PDC by phosphorylating serine residues of the E1α subunit, while PDPs activate the 
complex by dephosphorylating the same residues (Brautigam et al., 2006; Harris et al., 2002; Wu et al., 
2000, 1999). There are four isozymes of PDK in mammals; PDK1-4, which are specifically distributed in 
different tissues and each show different specificities for one or more of the regul ation sites in the PDC 
(Patel and Korotchkina, 2003). PDK1 is expressed primarily in the heart, while  PDK2 is expressed in 
abundance in most tissues, PDK3 is expressed mostly in testes and PDK4 is expressed in skeletal muscle and 
heart (Bowker-Kinley et al., 1998). PDK is activated when bound to a lipoyl group in either E2 or E3BP. PDK 
then moves from one lipoyl domain to a lipoyl domain on another E2 or E3BP component, thereby 
phosphorylating E1 and inhibiting PDC activity (Harris et al., 2001; Patel and Korotchkina, 2003). PDK1-3 
bind most efficiently to the lipoyl group on the E2 component, whereas PDK4 binds most efficiently to the 
lipoyl group on E3BP and less efficiently to E2 (Mayers et al., 2005).  
 
PDP is a heterodimer composed of a catalytic subunit, which is a phosphatase and a regulatory subunit, 
which is a flavoprotein. There are two isoforms of PDP; PDP1 and PDP2, which are able to dephosphorylate 
sites in E1 and thereby activate the PDC (Harris et al., 2001; Patel and Korotchkina, 2003). PDP1 is mostly 
present in the heart and brain, whereas PDP2 is expressed in greater amounts in liver, kidney, brain and 
heart (Patel and Korotchkina, 2003).  
 
5.4 The role of PDC in diabetes 
Type 2 diabetes is characterized by hyperglycaemia, which is caused by several factors; insulin resistance 
and impairment in insulin secretion caused by β-cell dysfunction as well as excessive hepatic glucose 
production from gluconeogenesis (Mayers et al., 2005). In early stages of the disease, the β-cells adapt to 
insulin-resistance by augmenting their size and function. As nutrients are in excess, blood glucose levels as 
well as free fatty acid levels become elevated because of an alteration in the balance between glucose and 
lipid metabolic pathways (Randle et al., 1994). This has a negative impact on the β-cell function and leads to 
a decreased GSIS and β-cell dysfunction (Chang-Chen et al., 2008). As described, insulin secretion is 
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stimulated through a cascade of events, starting with the uptake and metabolism of glucose through 
glycolysis and formation of pyruvate.  
 
The activity of PDK is increased in most tissues in individuals with diabetes because intracellular acetyl-CoA 
and NADH levels are high due to accelerated fatty acid oxidation. The activity of PDP is decreased, due to 
high levels of NADH, which also reduces the activity of PDC (Patel et al., 1995; Wu et al., 2000). Thus, PDK 
isozymes activities are up-regulated by PDC reaction products and PDP is down-regulated, leaving PDC 
phosphorylated and inactive. Starvation and chemically induced diabetes increase the activity level of PDK2 
and 4 protein in liver and heart mitochondria of rats and decrease the level when treated with insulin 
(Sugden et al., 1998; Wu et al., 1998). During starving and diabetic conditions, energy supplies are scarce 
and PDC need to stop the conversion of glucose to pyruvate and the further generation of energy through 
the TCA cycle. 
 
It was shown that a knock-out of the PDC E1 component in murine β-cells impaired GSIS in vivo and in vitro 
(Srinivasan et al., 2010). This can be explained by the central role of PDC in insulin secretion from the β-
cells, because of its role in the generation of cellular ATP. It is possible that some acetyl-CoA is generated 
from other substrates like fatty acids and amino acids, but this study showed that these substrates were 
not sufficient to keep insulin levels normal and could therefore not compensate for the missing acetyl -CoA 
generated from the pyruvate decarboxylation through PDC. (Srinivasan et al., 2010) 
 
6 MicroRNA 
MiRNAs are small functional RNA molecules that regulate genes without being transcribed into protein. As 
opposed to tRNA and snRNA, which are synthesized continuously, miRNAs are synthesized as a response to 
molecular changes within cells (Hutvágner and Zamore, 2002). The function of miRNAs is to regulate gene 
expression. MiRNAs are found in intergenic regions in both sense and antisense orientations (Rana, 2007).  
The regulation by miRNAs has widespread implications and impacts on important processes e.g. cell 
proliferation, cell death, lipid metabolism in flies (Brennecke et al., 2003; Xu et al., 2003) and neuronal 
patterning in nematodes (Johnston and Hobert, 2003). Up until the discovery of miRNA regulation, the 
accepted idea was that gene expression was regulated only at the pre-transcriptional level (Bartel, 2004). 
The impact of miRNA regulation is defined by the specificity between the miRNA and the mRNA, how many 
targets each miRNA binds to and how many miRNAs bind to a single target (Bartel, 2004).  
 
It has been suggested that miRNA transcription is unrelated to the transcription of the genes that they 
regulate, since miRNA genes are located at distinct sites from the genes they are regulating. This argues 
that the transcription is initiated by other factors (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and 
Ambros, 2001). One quarter of the human miRNAs are however found in the introns of pre-mRNA, 
suggesting that these miRNAs do not have their own promoters but are processed from the introns of 
genes in which they are placed in (Aravin et al., 2003; Lagos-Quintana et al., 2003; Lai et al., 2003; Lim et al., 
2003). 
  
6.1 Biogenesis 
The biosynthesis of miRNA is illustrated in Figure 5. Initially, miRNA is transcribed by RNA polymerase II as a 
longer RNA, which assumes a double stranded stem-loop structure with wobble sequences. This structure, 
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containing a 5’ end cap structure and a polyA-tail, is the primary miRNA (pri-miRNA). The pri-miRNA is then 
processed by the RNase endonuclease activity of the Drosha-DGCR8 complex in the nucleus to the pre-
miRNA, a smaller molecule of approximately 70 nucleotides. The pre -miRNA is then transported to the 
cytoplasm where Dicer cuts the stem loop into a duplex of two single stranded fragments of approximately 
22 nucleotides to obtain the mature miRNA. The mature miRNA is then loaded onto the RNA induced 
silencing complex (RISC), which is a large complex, formed of several proteins, including Dicer. The RISC 
containing the miRNA is called the miRISC and bound to the target mRNA it can repress translation, as 
described below (Bartel, 2004; Rana, 2007). 
 
Figure 5 The Biogenesis of miRNAs. The miRNA is transcribed by RNA polymerase II in the nucleus into the pri-miRNA. The Drosha -
DGCR8 complex cleaves i t into the pre-miRNA, which is expelled from the nucleus and further processed by Dicer. Association of 
the RISC ma kes the miRNA ready to exert translational repress ion on target mRNAs  ei ther by deadenylation to induce mRNA 
degradation in P-bodies or by s torage of the repressed mRNA that in response to cel lular s timul i , can re -enter the trans lation 
pathway in the cytoplasm (Rana, 2007). 
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6.2 Gene regulation 
The binding site of the miRNA is called the seed sequence and consists of 6-8 nucleotides (Abrahante et al., 
2003; Ambros, 1989). MiRNAs bind imperfectly to 3’UTRs of target mRNAs and down-regulate gene 
expression. When the miRISC is bound to the target mRNA, translation is repressed and it can accumulate 
in P-bodies for storage until later use by re-entry into the cytoplasm in response to cellular stimuli (Figure 
5) (Chu and Rana, 2006; Rana, 2007).  
The binding of miRISC to a target mRNA leads to either repression of translation or to induction of 
degradation. Gene silencing by miRNAs function by three different mechanisms: 
 The initiation of translation can be repressed by inhibiting formation of the 80S ribosomal 
complex or by competition with initiation factors 
 MiRNAs can inhibit translation elongation of target mRNAs, possibly by premature dissociation of 
ribosomes 
 MiRNAs can induce degradation of the target mRNA either by deadenylation of the polyA -tail by 
recruitment of a decapping enzyme which destabilizes the mRNA or by a slicing mechanism by 
Ago2. 
(Sayed and Abdellatif, 2011) 
 
6.3 MicroRNA 29  
The mature miR-29 is confirmed in a wide range of species and is completely conserved in humans, rats and 
mice  (mirbase.org, 2013a).  In humans, miR-29 includes three paralogues; miR-29a, miR-29b and miR-29c, 
which are encoded by two different gene clusters; miR-29b2 and miR-29c on chromosome one and miR-
29a and miR-29b1 on chromosome seven. Both clusters are transcribed together polycistronic. The miR-29 
family members share the same seed sequence in the mature miRNA at nucleotide position two to seven 
and are predicted to silence more or less the same set of genes. One important difference between the 
miR-29s is the cellular localization. MiR-29a is primarily expressed in the cytoplasm whereas miR-29b and 
miR-29c are mainly found in the nucleus. (Kriegel et al., 2012) 
In the stem loop for miR-29a, there are two different mature miR-29a, 3p and 5p (Figure 6). In this study 
the miR-29a-3p was used, since this is the most common. The sequence for miR-29a-3p is: 5’ 
UAGCACCAUCUGAAAUCGGUUA 3’ (mirbase.org, 2013b). 
 
 
Figure 6 The stem-loop of human miR-29a. The miR-29a-5p is placed at nucleotide number 4 to 25 of the primary transcript and 
marked in blue. The  miR-29a-3p is  at nucleotide number 42 to 63 and marked in purple. 
 
6.4 MiR-29a in pancreatic β-cells and diabetes 
The miR-29 family has been implicated in pancreatic development; including -cell development and 
mutation or misexpression of the miR-29 family members could possibly lead to -cell pathologies 
(Fernandez-Valverde et al., 2011). Furthermore, expression of the miR-29 family in adipose tissue is 
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induced by high glucose and insulin levels and an over-expression of miR-29 leads to insulin resistance 
(Fernandez-Valverde et al., 2011; He et al., 2007; Herrera et al., 2009, 2010).  
An examination of 3T3-L1 adipocytes showed that miR-29a is up-regulated in response to high glucose 
levels. This could indicate that the increased expression of miR-29a in adipocytes is involved in the initial 
cellular responses to hyperglycemia and the early cellular events related to pathogenesis of type 2 diabetes 
(Herrera et al., 2010).  
 
He et al. (2007) has investigated the expression levels of miR-29 paralogues in response to insulin and 
glucose in normal and diabetic rats. They found that all three miR-29 paralogues were up-regulated in rats 
with type 2 diabetes compared to normal rats. By northern blotting they were able to further confirm the 
over-expression of the miR-29 family in diabetic rats in three insulin target tissues; skeletal muscle, adipose 
tissue and liver.  
An adenovirus-mediated over-expression of miR-29 a, b and c in 3T3-L1 adipocytes resulted in a reduction 
in insulin-stimulated glucose uptake, which can reflect the role of the miR-29 family in insulin resistance in 
type 2 diabetes.  Additionally, to mimic the insulin resistance in type 2 diabetes, they incubated 3T3-L1 
adipocytes with high levels of insulin and glucose, which resulted in up-regulation of miR-29a and b 
compared to cells with physiological glucose levels. This shows that constant high levels of insulin and 
glucose will enhance miR-29 expression and it concords with the theory that miR-29 paralogs are over-
expressed and involved in manifestation of type 2 diabetes (He et al., 2007).   
 
The miR-29 family is also of interest for type 1 diabetes. Roggli et al. (2012) have investigated non-obese 
diabetic (NOD) mice, as a model for type 1 diabetes. A characteristic of type 1 diabetes is the loss of β-cell 
function in response to pro-inflammatory cytokines. A microarray of the miRNAs involved in β-cell 
efficiency in prediabetic NOD mice revealed that all miR-29 paralogues are up-regulated in the phases 
preceding diabetes manifestation. The role of miR-29 in diabetic progression was further confirmed since 
all miR-29 paralogues were up-regulated after having exposed isolated human and mouse islets to pro-
inflammatory cytokines to mimic the onset of diabetes. An over-expression of the miR-29 family members 
in an insulinoma cell line (MIN6) and in dissociated islet cells impaired the glucose -induced insulin secretion 
which indicates that miR-29 is not only a symptom of type 1 diabetes progression but plays an active role in 
the β-cell dysfunction, characteristic in the onset of type 1 diabetes (Roggli et al., 2012). 
Zampetaki et al. (2010) revealed the plasma signature of certain miRNAs, in type 2 diabetes. MiR-29b levels 
were reduced in the preceding stages of diabetes manifestation and could therefore be a biomarker of the 
risk of developing type 2 diabetes. The reduced miR-29 levels are also suggesting an important role of miR-
29 in the onset of type 2 diabetes. 
 
The regulation of miR-29a levels by glucose was investigated in human islets of Langerhans and in rat  
pancreatic β-cells (INS-1E) (Bagge et al., 2012).  MiR-29a expression levels were increased by elevated 
glucose levels in both rat INS-1E -cell lines and in human islets of Langerhans. Increased miR-29a levels 
promoted the -cells to proliferate and the up-regulation of miR-29a by glucose is therefore suggested as a 
link between glucose-induced proliferation and -cell dysfunction (Bagge et al., 2012). It was likewise 
observed, that over-expression of miR-29a impaired the GSIS at high glucose levels and an inhibition or 
deletion of miR-29a improved it (Bagge et al., 2012). This illustrates how the up-regulation of miR29a in β-
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cells is a result of hyperglycemia and how miR-29a is related to β-cell dysfunction in the progression from 
impaired glucose tolerance to the onset of diabetes.  
The targets of miR-29a include proteins that are involved in normal -cell functions. Syntaxin-1a (stx-1a) is 
involved in the exocytosis of insulin in GSIS and lowered levels of  stx-1a may induce diabetes due to an 
impaired GSIS. Over-expression of miR-29a in INS-1E cells showed decreased levels of stx-1a mRNA and 
protein (Bagge et al., 2013). This concludes that stx-1a is a direct target of miR-29a and the over-expression 
of miR-29a may contribute to impaired insulin secretion.  
 
MiR-29a is involved in the down-regulation of the monocarboxylate transporter (MCT1) which facilitates 
the diffusion of lactate and pyruvate across the plasma membrane in -cells. MCT1 is normally a repressed 
gene in β-cells, which prevents insulin release triggered by lactate, which could lead to hypoglycemia during 
exercise. Under normal conditions in β-cells, miR-29a affects the MCT1 by silencing its function and thereby 
preventing the uptake of lactate. It has been shown that MCT1 is a target of miR-29a since inhibition of 
miR-29a in primary mouse islets up-regulates MCT1 mRNA (Pullen et al., 2011). Unintentional insulin 
secretion of the β-cells is thus prevented and normal insulin secretion sustained when MCT1 function is 
repressed by miR-29a. An over-expression of miR-29a does not change the function of MCT1. (Pullen et al., 
2011) 
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7 Experimental design 
7.1 Reporter gene analysis 
It is hypothesized that miR-29a inhibits the expression of PDHx through a binding site in the 3’UTR of the 
mRNA transcript. A lack of miR-29a binding is therefore thought to increase the translation of PDHx. To 
investigate the effect of miR-29a on the regulation of PDHx, rat insulinoma pancreatic β-cell lines were 
transfected with reporter vector. To quantify the expression and inhibition of PDHx, the hypothesized 
binding site for miR-29a is incorporated into a reporter gene vector in order to quantify translation levels of 
PDHxUTR by the activity of firefly (FF) luciferase. A reporter gene analysis was employed for studying PDHx 
regulation (Figure 7). In this method it was utilized that the 3’ UTR of PDHx was incorporated as an 
extension of luciferase before a poly (A) signal in a pMirTarget vector in order to produce a single mRNA for 
the two genes together and thus the luciferase activity will be dependent on PDHxUTR translation. The 
pMirTarget vector contains an internal ribosomal entry site (IRES) that ensures that the reporter gene is not 
translated in too high amounts so that the possible effect of miR-29a is not able to be seen. If miR-29a 
targets PDHxUTR, then the miRISC complex will bind and down-regulate translation and thus a lowered FF 
luciferase activity will be observed. 
 
 
Figure 7 Luciferase assay. To the left: Interaction between miRISC and 3’ UTR of a  target gene results in lowered translation levels  
and reduced FF luciferase expression. To the right: No interaction between miRISC and the 3’ UTR results in no effect on translation 
and thus  luci ferase activi ty. (Origene, 2014) 
 
We expect a mutation in the miR-29a binding site to prevent miR-29a binding to the 3’UTR of PDHx and 
hence we predict that the mutation leads to an increased luciferase activity compared with the wild type 
PDHxUTR. If indeed miR-29a binds to the UTR of PDHx, the cells expressing WT PDHxUTR will show a 
decreased level of FF luciferase. A version of PDHxUTR with a mutation in the expected binding site for miR-
29a was aimed to be obtained. The system was expected to show a higher amount of PDHx reporter gene 
expression in the reporter gene assay than of the wild type since miR-29a would not be able to bind to the 
mutated version. The experiment was conducted on two different cell lines which either had a constitutive 
over-expression of a wild type miR-29a-3p (miR-29a OE cell lines) or an over-expression of a different 
miRNA, which has no target site in the PDHxUTR and is therefore a negative target construct (NTC) and 
functions as a negative control. NTC cell lines do however have a basic expression of miR-29a. We received 
the cells with courtesy from Louise Torp Dalgaard.   
The INS-E1 cells were transfected with four different reporter vectors; pMirTarget, pGL4.23 stx-1a, pGL4.23 
mut, pGL4.23 per. pMirTarget contains the PDHxUTR, the gene of interest. Stx-1a has previously been 
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shown to bind miR-29a (Bagge et al., 2013) and thus allows us to compare our results with the results 
reported from the previous study. MiR-29a per contains a perfect binding site for miR-29a and miR-29a mut 
contains a mutated binding site of miR-29a per which prevents miR-29a to bind. The expected results are 
seen in Table 2. 
 
Table 2 Expected results for the luciferase assay. The NTC cel l line has lower FF luciferase activi ties, due to the basic expression of  
miR-29a.   
No. Vector Cell line Expected FF luciferase activity 
1 WT PDHxUTR NTC Low 
2 WT PDHxUTR miR-29a OE Even lower 
3 MUT PDHxUTR NTC High 
4 MUT PDHxUTR miR-29a OE High (similar to 3) 
5 miR-29a per NTC Lower 
6 miR-29a per miR-29a OE Lowest 
7 miR-29a mut NTC High (similar to 3 and 4) 
8 miR-29a mut miR-29a OE High (similar to 3,4 and 7) 
9 Stx-1a NTC Low (similar to 1) 
10 Stx-1a miR-29a OE Even lower (similar to 2) 
 
7.1.1 Normalization vectors 
The genes encoding FF luciferase, β-galactosidase and Renilla (RR) luciferase were used for this experiment.  
Normalization of the FF luciferase activity of the reporter vectors to the activity of the internal control 
minimizes experimental variability caused by differences in cell viability or transfection efficiency. The 
transfected cells were normalized to β-galatosidase, RR luciferase or protein concentration. Protein 
concentration is measurement in all cells, transfected and non-transfected. The which level of FF luciferase 
is thus normalized to the amount of cells rather than the amount of successfully transfected cells, which is 
not as optimal as normalizing to β-galatosidase or RR luciferase. When a normalization vector is used, we 
assume that there is the same level of successful transfections in all cell lines. The overall assumption is 
that there is the same distribution of transfected cells in the NTC and the miR-29a OE cell line and that the 
cell lines are equally responsive to transfection with the different plasmids. If a cell is transfected, copies of 
the FF luciferase reporter plasmid, the normalization plasmid, enter the cell in a somewhat similar ratio to 
their distribution in the mixture. The luciferase assay was set up in order to only measure the  cells that had 
been transfected. If the transfection efficiency were different in the cell lines, this would not have an effect 
on the results when normalizing to β-galactosidase or RR luciferase. The absolute level of FF and RR 
luciferase activities can thus be different in the cell lines, while the relative level is applicable as a 
normalization factor.  
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7.2 Mutagenesis 
7.2.1 Overlap-extension PCR 
Overlap-extension PCR produces an insert with the desired mutation (Figure 8). The insert could then be 
ligated into a vector and replace the non-mutated insert which had been removed by digestion. Two PCR 
fragments (blue and green) were produced by the use of two sets of forward and reverse primers (primer 
1F+1R and primer 2F+2R) (Figure 8.A); one primer in each set incorporates a mutation (primer 1R and 2F) 
and the two primers are reverse complementary to each other, both annealing imperfectly to the template 
plasmid. The mutation was thereby introduced into the two separate fragments of 325bp and 724bp, 
respectively (Figure 8.B). Because primer 1R and 2F are reverse complementary to each other, the two PCR 
products will have a partial overlap of 47bp, constituting the length of the two primers. The partial overlap 
in the two PCR products will allow opposite strands of the two PCR products to anneal (Figure 8.C) for 
further elongation into a longer total fragment of 1003bp (Figure 8.D) which is the length from primer 1F to 
primer 2R. After the amplification of the 1003bp fragment with the mutation, it is digested with restriction  
enzymes to produce sticky ends ready for insertion into the vector, which was digested with the same set 
of restriction enzymes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Principles of overlap extension PCR. A. Four primers annealing to a  fragment of the vector. Primer 1R and 2F incorporates  
the mutation, shown by a  wobble sequence. B. The two sets of primers give ri se to two PCR products ; each double s tranded and 
incorporating the mutation, marked by a  black dot. The fragments are of different s izes.  C. PCR fragments of oppos i te s trands  wi l l  
anneal due to a  partial overlap caused by re verse complementarity of primer 1R and 2F. D. By extension PCR, the fragments  wi l l  be 
elongated in to longer tota l  fragments  incorporating the mutation. R: Reverse, F: forward. 
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7.2.2 Whole plasmid PCR and InFusion cloning 
In this procedure the pMirTarget vector and the two primers, which incorporate the mutation (primer 1R 
and 2F) were utilized (Figure 9A). 
The elongation time was extended compared to the overlap-extension PCR in order to produce PCR 
fragments of the whole vectors. The primers run in opposite directions and thus the first cycle will produce 
one strand with the mutation incorporated (Figure 9.B). After several cycles, the mutation will be 
incorporated in several linearized copies of the plasmid. Using cloning enhancer, the methylated template 
DNA was removed in order to obtain the newly synthesized DNA. Finally, a crossover between the 
homologue regions could be initiated (Figure 9.C), thus obtaining a circular plasmid ready for 
transformation (Figure 9.D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3 pMirTarget Vector 
The binding between miR-29a and the 3’UTR of PDHx was tested using a pMirTarget vector, containing the 
PDHxUTR gene (Origene, 2014) (Figure 10). The vector retains the human 3’UTR of PDHx, which is valid to 
utilize in the experiment since the 3’UTR’s seed sequence i s identical in humans and rats (mirbase.org, 
2013c). 
 
  
Figure 9 Whole plasmid PCR and InFusion cloning. A. The pMirTarget PDHxUTR vector i s used as template where the two primers 
incorporating the mutation anneal. B. The primers elongate through a length of the whole plasmid and possibly even longer. 
Reverse primers will then anneal to the single stranded DNA for further amplification of the whole plasmid. C. InFusion cloning 
mediates a  single crossover somewhere in the overlapping region that constitute the length of the primers. D. after crossover, the 
overlap region is removed and a  circular plasmid is obtained. 
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The vector includes the following: 
 Neo/Kanr - Neomycin and kanamycin resistance genes in eukaryotes and prokaryotes, respectively.  
 SV40 – Constitutive promoter for the Neo/Kanr and luciferase 
 IRES – Internal ribosome entry site, an alternative site for translation initiation. 
 Luciferase – The gene for the luciferase enzyme. 
 PolyA – Signal for the production of a polyA-tail on the mRNA. 
 ColE1 – The origin of replication 
 OriF1 – F1 phage origin (Not used) 
 CMV – Promoter for RFP 
 RFP – Red fluorescent protein 
 PDHxUTR – inserted between AscI and RsrII between the luciferase and polyA signal (Not seen in 
Figure 10). 
 
 
Figure 10 pMirTarget vector. pMirTarget vector with included genes, DNA sequences and restriction sites in the multi cloning s i te. 
(Origene, 2014) 
 
7.4 Design of mutation 
To prevent miR-29a from binding to the UTR of PDHx, a mutation was introduced. MiRNAs bind to their 
targets by a seed region of typically seven nucleotides (Bartel, 2004). MiR-29a and the complementary 
sequence of the mRNA of PDHxUTR are seen in Figure 11 and include seven bases – however, some base 
pairing is also able to occur upstream from the seed sequence. The miR-29a seed sequence is at 252bp to 
258bp on the UTR of PDHx and it is where the mutation was introduced. 
 
Figure 11 MiR-29a and binding site of PDHx-UTR. Seed sequence is green and other complementary base pa irs  upstream are 
marked in blue. 
  
The seed sequence is seven base pairs, which makes it reasonable to alter three bases within this sequence 
to ensure the lack of binding. If too many bases were altered, there would be a risk of the p rimers not 
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binding to the template in the PCR reaction. The nucleotides are changed from pyrimidines into pyrimidines 
and from purines into purines to optimize binding of the primer. The mutation of PDHxUTR mRNA is seen in 
Figure 12. 
 
Figure 12 MiR-29a and the mutated binding site of PDHx-UTR. Seed sequence is green, mutated nucleotides are marked in red and 
other complementary base pa irs  upstream is  marked in blue. 
 
It is important to ensure that the new sequence does not interact with other miRNAs that are expressed in 
the cells and that it does not become a restriction site of the restriction enzymes, EcoRI and MluI, which 
were used for linearization. The mutated sequence did not introduce new restriction sites for EcoRI or MluI 
and it was compared with sequences from other miRNAs in TargetScan to search for possible miRNA 
binding sites. The sequence was investigated both forward (F) and reverse complementarity (RC) and in 
regions overlapping the mutated seed sequence were checked (Table 3). 
 
Table 3 Sequences used in the search for miRNA binding. Red depicts the changed nucleotides and underl ined nucleotides  are 
nucleotides upstream or downstream of the seed sequence. Both the forward sequences  (F) and reverse complementary 
sequences  (RC) are indicate d. Al l  sequences  are wri tten in 5’ to 3’ di rection. 
 F RC 
Wild type TGGTGCT AGCACCA 
Mutation TAGCGTT AACGCTA 
Upstream overlap CTCTAGC GCTAGAG 
Downstream overlap CGTTGTA TACAACG 
 
The only sequence that is expected to bind miR-29a is the wild type. According to TargetScan, the mutation 
will successfully prevent miR-29a from binding and further, no other miRNAs will bind to the tested 
sequences (TargetScan.org, 2012). This leads to the conclusion, that the designed mutation can be 
employed to test the possible binding of miR-29a to the 3’UTR of PDHx.  
 
An IntaRNA analysis of the miR-29a binding site of the wild type and the mutated version was conducted, 
to examine whether the mutation reduces the binding energy of miR-29a significantly or completely, as it is 
expected to do (Uni Freiburg, 2014). We tested approximately 100bp both upstream and downstream of 
the target site. The wild type showed a binding energy of -8.35 kcal/mole in the target site while the 
mutant showed  -2.75014 kcal/mole, which was in another region in the UTR than the target site of the wild 
type. This confirms that miR-29a will not bind to the mutant. 
 
7.5 Design of primers 
The primers used for the mutagenesis are shown below. Orange represents restriction sites where primer 1 
has a site for EcoRI and primer 4 has a restriction site for MluI. Green constitutes the mutated target site. 
Note that primer 3 is reverse complementary of primer 2. The sites of primer annealing on the vector can 
be seen in Appendix 13.1.  
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Forward primers: 
Primer1: TGGCAGAGCTCAGAATTCAA 
Primer2: TCAGATCCATTTTTAACCTCTAGCGTTGTATAAAGGGAATATTAAAC 
 
Reverse primers: 
Primer3: GTTTAATATTCCCTTTATACAACGCTAGAGGTTAAAAATGGATCTGA 
Primer4: CCGCTTACGCGTCAAGGTTTA 
 
8 Materials and methods 
8.1 Work flow 
The experiment was designed to include both a 
mutated and a non-mutated PDHxUTR, thus a 
mutagenesis of the PDHxUTR was conducted parallel 
to the reporter gene analysis of the non-mutated 
PDHxUTR (Figure 13). The vector containing the gene 
of interest for both the mutated and non-mutated 
version of PDHxUTR was pMirTarget. The PDHxUTR 
was incorporated as an extension of FF luciferase.  
pMirTarget was amplified and purified by 
transformation of competent E. coli cells, with a 
subsequent maxiprep. The purified vectors were used 
directly in the reporter gene analysis by transfection of 
INS-1E cells. The purified vector was also utilized for a 
mutagenesis of the binding site of miR-29a in 
PDHxUTR. The vectors containing the mutated insert 
were transformed into competent E. coli cells. From 
this transformation, a miniprep was prepared to purify 
the vectors for restriction fragment analysis which 
would verify that the altered insert had been 
incorporated. Plasmids from the miniprep were 
supposed to be sent to sequencing, to ensure the 
presence of the desired mutation. After sequencing, a 
maxiprep was planned to increase the amount of 
purified plasmids. The reporter gene analysis would 
have been carried out with the same method applied 
as for the non-mutated pMirTarget. 
 
8.2 General procedures 
8.2.1 Transformations 
Different competent cells were investigated in order to determine a working concentration of kanamycin 
and to find the most suitable competent cells (Table 4). 
 
Figure 13 Overview of workflow. Two para llel experiments 
were conducted; one for the wild type and one for the 
mutant. White boxes represents steps that were completed. 
Grey boxes represents intended s teps that were not 
completed.  
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Table 4 No. of colonies with transformations of competent E. coli cells with pMirTarget PDHxUTR. Al l  trans formations  were 
accompanied by transformations with control; pGL4-vegfa promoter (6kb) on an ampici l l in concentration of 100 µg/mL which 
yielded > 300 colonies  at a l l  times . 
 Kanamycin concentration (µg/mL) 
Competent cell line 50 25 15 
DH5X conventional  - >> 300 >> 300 
DH5X heat - 0 0 
One Shot® Top10 - > 300 > 300 
 
Based on the results from the first transformations, it was decided that all transformations would be 
performed with One Shot® TOP10 chemically competent E. coli bacteria cells (Life Technologies) and that 
all transformations with pMirTarget PDHxUTR would be plated on 25µg/mL Kanamycin LB-plates while the 
positive control pGL4-vegfa promoter would be plated on 100µg/mL ampicillin LB plates. All competent 
cells were placed on ice for 30 minutes before heat shock at 42oC for 30 seconds. Subsequently the samples 
were placed on ice for 2 minutes before adding media containing the vector. The samples were incubated 
at 37oC for 30 minutes to 1 hour before plating.  All transformations were incubated at 37°C overnight or at 
room temperature for 48 hours.  
 
8.2.2 Gels 
All gels were ~1% agarose and placed in 1xTAE buffer, 5-10 µL 10 mg/mL ethidium bromide was added to 
the gel and buffer for DNA visualization. The band separation was performed at 110-130 mV until clear 
separated bands appeared (approximately after 30-50 minutes). For all gel extractions the QIAquick Gel 
Extraction Kit from QIAGEN (Cat no. 28704) was utilized.  
 
8.2.3 Plasmid preparations 
All minipreps were carried out using the Pure Link Quick Plasmid Miniprep Kit (Invitrogen, Cat no. K2100-
10) and all maxipreps were carried out using the Nucleo Bond Xtra Maxi (Macherey -Nagel, Cat no. 
740414.50) 
 
8.2.4 Statistics 
T-tests were conducted for all data presented in figures in results (section 9.2). F-tests for two samples 
were performed in order to determine equal or unequal variances. T-tests for two-samples were then 
conducted for the type of variance, detected by the F-test. All data and statistical data are found in 
Appendix 13.2, 13.3, 13.4 and 13.5. The level of significance was set to be α = 0.05. All p-values lower than 
0.001 are designated p < 0.001. Sample sizes (designated n) reflect the sample size per group in one 
experiment. 
 
8.3 Mutagenesis 
Two different methods were applied in the effort to obtain the mutant PDHxUTR as an extension of 
luciferase in the pMirTarget PDHxUTR vector: Overlap-extension PCR and whole plasmid PCR with In Fusion 
cloning. All of the experiments described below involve the same set of primers, as described in section 7.5. 
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8.3.1 Overlap-extension PCR of pMirTarget 
PCR reactions were set up to introduce a mutation into PDHxUTR in the pMirTarget vector (PCR1, Table 5) 
and to extend the mutated fragments obtained by the previous reaction (PCR2,  
Table 6). See section 7.2.1.  
 
Table 5 PCR1. A. The final concentration and the amount of reagent added to the PCR reaction.  B. Setup of the cycles  and 
temperatures. Sample A had an annealing temperature of 56°C, B had an anneal ing temperature of 58°C, C had an anneal ing 
temperature of 60°C and sample D had a n anneal ing temperature of 62°C. Each sample was  made in quadrupl icates  ( 1-4). 
A Final conc.  
(ng/µL) 
Mixture (µL)  B PCR setup 
  A B C D  Cycles Time (min) Temperature (°C) 
H2O  9.5 9.5 9.5 9.5  1 2:20 98 
5x HF buffer  - 5 - 5  35 0:10 98 
5x GC buffer  5 - 5 -   0:10 56  58  60  62 
dNTP (2mM) 5 2.5 2.5 2.5 2.5   0:15 72 
Primer 1F (10 µM) 12.5 1.25 1.25 - -  1 5:00 72 
Primer 1R(10 µM) 12.5 1.25 1.25 - -  1 ∞ 4 
Primer 2F (10 µM) 12.5 - - 1.25 1.25     
Primer 2R (10 µM) 12.5 - - 1.25 1.25     
DNA polymerase 
(2U/ µL) 
 0.5 0.5 0.5 0.5     
Template(2ng/ µL) 10 5 5 5 5     
Total volume  25 25 25 25     
 
 
Table 6 PCR2 A. Final concentrations and amount of reagent added pr. reaction. B. Setup of cycles and temperatures  for the PCR. 
A                        Final conc.  
(ng/µL) 
Mixture (µL)  B              PCR setup 
H2O  12.2  Cycles Time (min) Temperature (°C) 
5x HF buffer  5  1 0:30 98 
dNTP (2mM)  2.5  25 0:05 98 
Primer 1F (10 µM) 12.5 1.25   0:10 55 
Primer 2R(10 µM) 12.5 1.25   0:20 72 
DNA polymerase (2U/ µL)  0.5  1 5:00 72 
Template B2, 350bp (15ng/µL) 15 1  1 ∞ 4 
Template C3, 725bp (23.5ng/µL) 30.55 1.3     
Total volume  25     
 
The template DNA for PCR2 is the product of PCR1. Apart from the template DNA, the only difference 
between the two reactions is that in PCR1 two different buffers were tested, HF and GC buffer. HF, high 
fidelity, buffer reduces the risk of introducing random mutations during the PCR, which makes the reaction 
a little slower. GC buffer is faster but not as reliable. As we saw no difference in the results from reactions 
with the two buffers, HF buffer was chosen for the proceeding reactions.  The 1002bp fragment, which was 
the product of PCR2, was digested with EcoRI and MluI to introduce sticky ends that would be compatible 
with the sticky ends of the pMirTarget PDHxUTR vector, digested with the same restriction enzymes.  
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8.3.1.1 Digestion of pMirTarget 
As described above, MluI and EcoRI were utilized for all digestions of pMirTarget and for all the inserts that 
were intended for ligation with pMirTarget. pMirTarget has restriction sites at the multi cloning site of 
PDHxUTR (Figure 10). The restriction sites for MluI and EcoRI are: 
 
 
8.3.1.2 Ligation of pMirTarget with insert 
All ligations were carried out with T4 DNA ligation kit (Thermo Scientific, Cat no. EL0014). Five ligations 
(ligation 1-5) were conducted with pMirTarget PDHxUTR vector and the mutated insert. Ligation 1-4 had a 
molar vector-insert ratio of 1:1 while ligation 5 had a molar vector-insert ratio of 1:5. Ligation 1-3 had an 
incubation time of 5 min, ligation 4 and 5 had an incubation time of 10 min. Apart from the molar ratio and 
the incubation time all samples were treated the same according to Table 7. The molar ratio and incubation 
time were changed to optimize the ligation. 
 
Table 7 Ligation of pMirTarget with the mutated insert.  
 Final conc.  Vector:insert molar ratio (volumes in µL) 
 (ng/µL) 1:1 1:5 1:0 
5x DNA dilution buffer  2 4 2 
Insert (23.5 ng/µL) 10   13   0 4.3 11  
Vector (28.4 ng/µL) 10   2.6 10 3.5 1.8 3.5 
H2O  0.2 3.2 4.5 
Total  10 20 10 
T4 DNA Ligation buffer  10 20 10 
T4 DNA ligase  1 2 1 
  
All ligations were followed by transformation for subsequently purification of the pMirTarget PDHxUTR mut 
vector. 
 
8.3.2 Whole plasmid PCR and In Fusion Cloning  
Three whole-plasmid PCR reactions were completed. For optimization of the reaction, different recipes 
were tested (Table 8). The buffer was changed from HF to GC buffer, the amount of nucleotides and DNA 
polymerase were increased and different amounts of DNA template were tested. All reactions were carried 
out with the same number of cycles but with different annealing temperatures and different elongation 
times (Table 9).  
When performing the whole plasmid PCR, the PCR must be set up in orde r to denature the whole plasmid. 
Too few PCR cycles may not amplify enough DNA to be visible on a gel, while too many cycles allow non-
specific amplification and increase the chances of introducing point mutations by the polymerase. The 
whole plasmid PCR was therefore performed with a few cycles first at a lower temperature and thereafter 
more cycles at a higher temperatures. This is done due to initially imperfect binding of the primers to the 
template DNA whereas there exists a fully complementary region after the first cycles.  
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Table 8 The concentrations of the reagents for whole-plasmid PCR 
 Final conc.  
 
1
st
 reaction (µL) 2
nd
 reaction 
(µL) 
3
rd
 reaction 
(µL) 
H2O  13.1 13.1 & 11.1 13 & 13.5 
5x HF buffer  0.4 0.4 - 
5x GC buffer  - - 0.4 
dNTP (2mM)  2 2 2 
Primer 1F (10µM)  1 1 1 
Primer 2R (10µM)  1 1 1 
DMSO 100% 3% -  0.6 
Template (2   2  10  100ng/µL) 4,   4&8,   10&50ng 2 2 & 4 1 & 0.5  
DNA polymerase (2U/µL)  0.5 0.5 1 
Total  20 20 20 
 
Table 9 Changes in PCR setup for annealing and extension times and temperatures. 
Cycles 1
st
 Reaction 2
nd
 Reaction 3
rd
 Reaction 
Process No.   Elongation 
time (min) 
Annealing 
temp. 
Elongation 
time (min) 
Annealing 
temp. 
Elongation 
time (min) 
Annealing 
temp. 
First annealing & 
extension 
7 3:00 60 3:00 48   56   60 4:00 46  48  50  54 
Second annealing 
& extension 
30 3:00 67 3:00 55   60   67 4:00 56 
 
8.4 Transfection and reporter gene analysis  
As described in section 7.1, the transfections with pMirTarget PDHxUTR were conducted using two 
different cell systems. In the first three transfections INS-1E cells with a constitutive endogenous 
production of miR-29a were used and NTC cells were used as control. For the fourth transfection transient 
mimic miR-29a oligonucleotides (negative and positive) were dripped onto the INS-1E cells to obtain either 
normal or increased levels of miR-29a, respectively.  
Transfection of the INS-E1 cells were carried out by the use of lipofectamine which has a positively charged 
ammonium ion head group that will attract and coat negatively charged phosphorous groups in the DNA, 
forming liposomes. The liposomes can then insert the DNA into the cell by fusing with the cell memb ranes 
of the INS-1E-cells.  
The INS-1E cells were grown 24 hours prior to transfection and 48 hours after transfection before 
harvesting. All transfections were carried out using Lipofectamine 2000 reagent™ (Invitrogen by Life 
Technologies Cat no. 11668) Prior to transfection, all vector samples were incubated with 1ng per 48-well 
for 20 minutes at room temperature before vectors were added to the cells. Four different reporter vectors 
were utilized all containing the FF luciferase gene; pMirTarget, pGL4.23 miR-29a per, pGL4.23 miR-29a mut 
and pGL4.23 stx-1a. The expected results for the different vectors are shown in Table 2. 
 
All cells were harvested by the Dual-Light assay system (Applied Biosystems, Cat no. BD100LP), which was 
also used when the luciferase activities were measured for pCMV-LacZ encoding β-galactosidase. The Dual-
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Luciferase Reporter Assay System (Promega, Cat no. E1910) was used for measurement when transfecting 
with pRL-SV40 encoding RR luciferase. Protein concentrations were determined using the Pierce BCA 
Protein Assay Kit (Thermoscientific, Cat no. 23225). In the following, the concentrations of the different 
reagents are shown for the four transfections.  
 
8.4.1 Transfection 1 
The first transfection was conducted using the vectors pCMV-LacZ, pGL4.23 miR-29a mut, pGL4.23 stx-1a 
and pMirTarget PDHxUTR. The three mixtures, A, B and C all contain the following plasmids: 
 pCMV-LacZ vector to normalize the FF luciferase activity to β-galactosidase activity 
 Luciferase reporter vectors to measure FF luciferase activities in relation to miR-29a binding 
 Sk+ pBluescript vector to obtain the optimal total plasmid concentration of 600ng/48-well 
 
Table 10 Mixture for transfection 1. Each mix i s  prepared for 8 wel ls . 
 Final conc. A B C 
 (ng/48-well) (µL) 
Sk+ (480 ng/µL) 480 8 8 8 
pCMV-lacZ (10ng/ µL) 20 16 16 16 
Reporter vector (100 ng/µL)     
Syntaxin-perfect 100 8 - - 
miR-29a scrambled 100 - 8 - 
pMirTarget 100 - - 8 
RPMI Media  200 200 200 
LF-media mix  200 200 200 
 
8.4.2 Transfection 2 
The second transfection was conducted with both the Dual-Light and the Dual-Luciferase assay with pCMV-
LacZ and pRL-SV40, respectively (Table 11). Apart from the addition of pRL-SV40 the assay was conducted 
with the same vectors as for Transformation 1. 
 
Table 11 Transfection 2. A-D: Normalization vector pRL-SV40 to express RR luci ferase. E-F: Normal ization vector pCMV-LacZ to 
express  β-ga lactos idase. Al l  mixes  are made for 8 48-wel ls . 
 Final conc. A B C D E F 
 (ng/48-well) (µL) 
Sk+ (480ng/µL) 480 8 8 8 8 8 8 
pCMV-LacZ (10ng/µL) 10 - - - - 8 8 
pRL-SV40 (1ng/µL) 10 80 80 80 80 - - 
Reporter vector(100ng/µL)        
Syntaxin 100 8 - - - 8 - 
miR-29a scrambled 100 - 8 - - - - 
pMirTarget
* 
100 - - - 8 - - 
RPMI Media  200 200 200 200 200 200 
LF-media mix  200 200 200 200 200 200 
*pMirTarget vector was  dripped on the cel l s  on hour later, see text. 
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During this transfection, the pMirTarget PDHxUTR vector was added one hour later to the cells that 
received mixture D. In half of the wells the vector was dripped on the cells without any preparation while in 
the other half pMirTaget PDHxUTR was incubated with extra lipofectamine mixture before addition to the 
wells.  
 
8.4.3 Transfection 3 
Reduced concentration of pRL-SV40 was utilized in transfection 3 as well as the pGL4-stx-1a vector being 
exchanged for pGL-miR-29a per vector. Apart from these changes the same vectors as for Transfection 2 
were used. 
Table 12 Transfection 4. A-D: Normalization vector to renilla luciferase. E-F: Normalization vector to β-ga lactosidase. All mixes  are 
made for 8 48-wel ls . 
 Concentration  A  B  C  D  E  F 
 (ng/48-well) (µL) 
Sk+ (499ng/µL) 499 8 8 8 8 8 8 
pCMV-LacZ (1ng/µL) 1 - - - - 8 8 
pRL-SV40 (1ng/µL) 2 16 16 16 16 - - 
Reporter vector        
miR-29a per (100ng/µL) 100 8 - - - 8 - 
miR-29a mut (100ng/µL) 100 - 8 - - - - 
PDHxUTR (100ng/ µL)
 
100 - - - 8 - - 
RPMI Media  200 200 200 200 200 200 
LF-media mix  200 200 200 200 200 200 
 
8.4.4 Transfection 4 
In transfection 4, INS-1E cells without a constitutive production of miR-29a were used according to the 
Thermo Scientific miRIDIAN shMIMIC Lentiviral microRNA Technical Manual  (Thermoscientific Cat no. 
VSR6261). MiR-29a positive and negative mimic oligos (miRIDIAN microRNA Mimics from Dharmacon, 
ThermoFisher Scientific) were dripped onto the cells to mimic normal and over-expressed levels of miR-
29a. The added mimic oligos were ds-siRNAs which only had to penetrate the plasma membrane and be 
loaded onto the RISC complex in the cytoplasm in order to function as a miRNA.   
 
Table 13 Transfection 4 Al l  mixes  are made for 8 48-wel ls . Mimic ol igo consti tute volumes  for 4 48-wel ls . 
 Concentration A B C 
 (ng/48-well) (µL) 
Sk+ (498g/µL) 498 8 8 8 
pRL-SV40 (1ng/µL) 2 16 16 16 
Reporter vector     
miR-29a per (100ng/µL) 100 8 - - 
miR-29a scr (100ng/µL) 100 - 8 - 
pMirTarget (100ng/ µL)
 
100 - - 8 
RPMI Media  200 200 200 
LF-media mix  200 200 200 
MiR-29a mimic (20pmol/µl) 25pmol/µl 5.2 5.2 5.2 
Mimic negative (20pmol/µl) 25pmol/µl 5.2 5.2 5.2 
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9 Results 
9.1 Mutagenesis 
It was attempted to introduce the mutation in the pMirTarget PDHxUTR vector by overlap-extension PCR 
and whole plasmid PCR. In the following the results from the mutagenesis will be presented.  
 
9.1.1 Overlap-extension PCR of pMirTarget 
9.1.1.1 Digestion of pMirTarget 
The digestion of pMirTaget PDHxUTR with EcoRI and MluI is seen in Figure 14. The expected size of the 
digested vector is 7kb while a semi-completed digestion should produce bands at 8kb. The band at 1kb is 
the fragment removed by digestion. Due to time limitations it was not possible to run the gel long enough 
for a separation of the 7kb and 8kb bands. The separation of the bands would be ideal, but since this was 
not possible, the combined 7kb and 8kb bands were extracted (10.9ng/µL) and used for further 
experiments.  
 
Figure 14 The digestion of pMirTarget with EcoRI and MluI. The vector was amplified and purified through a maxiprep. The bands  
are clearly discernible in the area of 7000bp, which is the expected length of the digested vector. The molecular weight size marker 
i s  Generuler™ 1 kb plus  DNA ladder (Thermo Scienti fic).  
 
9.1.1.2 Mutagenesis of insert 
The results from the PCR introducing the mutation and the overlap-extension are shown in Figure 15. B2 
(325 bp) and C3 (724 bp) (Figure 15.A) were extracted (B2: 15ng/µL and C3: 23.5ng/µL) and utilized for the 
subsequent overlap-extension PCR (Figure 15.B). The overlap extension PCR yielded the expected fragment 
at 1002 bp and after extraction DNA concentrations were 27.7ng/µL and 30.5ng/µL, respectively. The 
overlap-extension PCR was subsequently digested with EcoRI and MluI, which produced sticky ends for the 
ligation with pMirTarget. 
 
Figure 15. Overlap-extension PCR of pMirTarget A. Introduction of mutation in PDHxUTR in two fragments. A and B samples  were 
run with primer 1F and 1R which yielded the fragment of 325bp. C and D samples were run with primer 2F and 2R which yields  the 
fragment of 724bp. Annealing temperatures were distributed as follows: Sample 1: 58°C, sample 2:60°C, sample 3: 62°C and sample 
4: 62°C. B. Extens ion PCR based on B2 and C3 from A. The annealing temperature was 55°C. Molecular weight s ize -markers  for A 
and B: GenerulerTM 100bp plus  DNA ladder (Thermo Scienti fic). MW: molecular weight s ize -marker.   
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9.1.1.3 Ligation and transformation of vector and insert 
The results of ligations between the digested pMirTarget vector (7kb) and the mutated insert ( 1kb) are 
show in Table 14. Because the ligations continuously did not yield any transformed colonies, optimizations 
were applied as the project progressed. The optimizations consisted of changing the amount of dilution 
buffer added to the ligation reaction and by changing the vector-insert ratio. Additionally, new digestions of 
pMirTarget and the insert were conducted for ligation 3, 4 and 5 to minimize the possibility of working with 
only partly digested DNA fragments. As is evident from Table 14 the endeavors did not result in a successful 
ligation, which in turn resulted in a lack of obtaining the mutated pMirTarget vector for examining in the 
reporter gene analysis. 
 
Table 14 Overview of results from ligation and transformation of PDHxUTR mut insert with pMirTarget in E. coli top 10 cel l s . 
Ligation Molar ratio 
(Vector:Insert) 
Amount 
(Vector:Insert) 
pMirTarget Positive control 
pGL.4-VEGFA promoter 
Negative control 
Vector, no insert 
   No. of colonies on the plates  
1 1:1 1:5 0 >300 0 
2 1:1 1:5 1 >300 0 
3 1:1 1:5 1 >300 4 
4 1:1 1:5 0 >300 0 
5 5:1 1:1 0 >300 0 
                       
Ligation 2 resulted in 1 colony. The colony was used to produce two minipreps with a DNA content of 
6.2ng/µL and 13ng/µL respectively. The samples were pooled and digested with EcoRI and MluI, but did not 
show any visible bands in gel electrophoresis as seen in Figure 16. The pMirTarget PDHxUTR vector 
digested with EcoRI and MluI showed bands at 1kb and 7kb. The samples from the mutagenesis did thus 
not contain the pMirTarget vector, and the colony used for the miniprep could have developed kanamycin 
resistance spontaneously. 
 
Figure 16 Digestion of pMirTarget PDHxUTR mut (M1 and M2) and pMirTarget PDHxUTR (WT1 and WT2). There are no vis ible 
bands for the pMirTarget PDHxUTR mut at 1kb or 7kb while two clear visible bands are seen for pMirTarget PDHxUTR at 1kb and 
7kbp, respectively.   
 
9.1.2 Whole plasmid PCR of pMirTarget PDHxUTR 
Since the PCRs failed to amplify, optimizations were attempted. The annealing temperatures, elongation 
times and recipes for the PCR reactions were changed between each PCR, but as none of the gels show ed 
any bands, this will not be described in detail. 
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9.2 Reporter gene analysis 
9.2.1 Transfection 1 
The first transfection was performed with the reporter vectors pGL4.23 stx-1a, pGL4.23 miR-29a mut and 
pMirTarget PDHxUTR. The FF luciferase activities were normalized for β-galactosidase (pCMV-LacZ) and the 
protein content (Figure 17). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results indicate no significant difference between the luciferase activities normalized for β-
galactosidase activity between the NTC cell lines and the miR-29a OE cell lines (miR-29a mut: p = 0.554; Stx-
1a: p = 0.560; PDHxUTR: p = 0.301) (Figure 17.A). The results were expected to show a decrease in 
normalized FF luciferase activity for stx-1a when expressed in miR-29a OE cells. Since the normalized FF 
luciferase activity for stx-1a was not significantly decreased between the cell lines, the results normalized 
for β-galactosidase activity are not reliable and thus it is not possible to detect whether miR-29a binds to 
PDHxUTR.  
There is a significant decrease in β-galactosidase activity of 64.2%, 58.1% and 66.3% from the NTC cell lines 
to their miR-29a OE counterpart for miR-29a mut (p < 0.001), stx-1 (p = 0.002) and PDHxUTR (p < 0.001), 
respectively (Figure 17.B). Since the reduction in β-galactosidase activity is significant and is consistent for 
each pair of cell lines, the reduction cannot be attributed to randomness or to a difference in transf ection 
success. Thus, the β-galactosidase activity must be affected by the type of cell it is expressed in. This 
reduces the reliability of the normalized luciferase activities. Since the β-galactosidase activity is dependent 
on the type of cell line it is expressed in, it cannot be utilized as a proper normalization factor. These results 
Figure 17 Transfection 1. A. FF Luci ferase activities normalized for β-galactosidase activities (miR-29a mut: n = 4, p = 0.554; Stx-1a: 
n = 4, p = 0.560; PDHxUTR: n = 4, p = 0.301). Al l  samples are relative to miR-29a mut in NTC cells. B. Raw β-galactosidase activi ties  
(miR-29a mut: n = 4, p < 0.001; Stx-1a: n = 4, p = 0.002; PDHxUTR: n = 4, p < 0.001). C. FF Luci ferase activi ties  normal ized for 
protein concentrations (miR-29a mut: n = 4, p = 0.005; Stx-1a: n = 4, p < 0.001; PDHxUTR: n = 4, p = 0.036). Al l  samples are relative 
to miR-29a mut in NTC cells. D. Protein concentrations in mg/mL (miR-29a mut: n = 4, p = 0.008; Stx-1a: n = 4, p = 0.014; PDHxUTR: 
n = 4, p = 0.437). 
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indicate that miR-29a affects the expression of the pCMV-LacZ normalization vector, which causes a 
decrease in β-galactosidase activity. This makes it impossible to verify a possible binding between miR-29a 
and PDHxUTR, using the pCMV-LacZ vector for normalization.  
Normalization of FF luciferase activity to protein concentration was included in the effort t o obtain an 
efficient normalization factor (Figure 17.C). The results show a significant decrease in FF luciferase activity 
from the NTC cells to the miR-29a OE cells of 81.4% for miR-29a mut (p = 0.005) 74.6% for Stx-1a (p < 0.001) 
and 76.3% for PDHxUTR (p = 0.036). The significant decrease in FF luciferase activity of the cells transfected 
with stx-1a and PDHxUTR could reflect a binding of miR-29a, but since this decrease is also seen in cell lines 
transfected with miR-29a mut, the decrease of stx-1a and PDHxUTR cannot with certainty reflect binding of 
miR-29a.  
There is no significant difference in protein concentration between the NTC cell line and the miR-29a OE 
cell line transfected with PDHxUTR (p = 0.437), however a significant difference is seen in protein levels 
between the two cell lines transfected with both miR-29a-mut (p = 0.008) and stx-1a (p = 0.014). A 
significant reduction in protein levels between the cell lines implies that the system not only has a bias in 
regard to pCMV-LacZ, but also in cell growth.  
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9.2.2 Transfection 2 
In this experiment, the main alteration was that the FF luciferase activity was normalized to RR luciferase 
activity encoded in pRL-SV40 vector instead of β-galactosidase encoded in pCMV-LacZ. The purpose was to 
obtain normalization factors that were independent of the cell line. The results are presented in Figure 18. 
 
The data show a significant decrease of FF luciferase activity normalized to RR luciferase between the NTC 
cell line and the miR-29a OE cell lines for miR-29a-mut (p = 0.001) of 37.1% (Figure 18.A). This is 
unexpected since miR-29a is prevented from binding and thus should not be able to lower the luciferase 
activity. For stx-1a, the activity increased 25.5 % from the NTC to the miR-29a OE cell line (p = 0.166), which 
is in contrast to the effect of miR-29a binding to the mRNA of stx-1a, as reported by Bagge et al. (2013). FF 
luciferase activities decreased 28.7% between the NTC cell line and the miR-29a OE cell line for PDHxUTR (p 
= 0.383), which seems reasonable if miR-29a binds to PDHxUTR. Further, it is seen that RR luciferase counts 
are decreased in the miR-29a OE cells, compared to the NTC cell line with 32.2% for miR-29a mut (p = 
0.056), 33.7% for Stx-1a (p = 0.060) and 30.7% for PDHxUTR (p = 0.125) (Figure 18.B). Even though the 
difference between RR luciferase activities in the cell lines are not significant and are lower than the 
differences in β-galactosidase activities in transfection 1, all of the samples show a trend towards having RR 
luciferase activities that are affected by the cell type. To examine whethe r RR luciferase activities are 
Figure 18 Transfection 2 A. FF Luci ferase activities normalized for RR luciferase activities (miR-29a mut: n = 4, p = 0.001; Stx-1a: n = 
4, p = 0.166; PDHxUTR: n = 2, p = 0.383). Al l  samples are relative to miR-29a mut in NTC cells. B. RR luci ferase activi ties  (miR-29a 
mut: n = 4, p = 0.056; Stx-1a: n = 4, p = 0.060; PDHxUTR: n = 2, p = 0.125; R luc only: n = 4, p < 0.001). C. FF Luci ferase activi ties  
normalized for the protein concentration (miR-29a mut: n = 4, p = 0.007; Stx-1a: n = 4, p = 0.043; PDHxUTR: n = 2, p = 0.041).  Al l  
samples are relative to miR-29a mut in NTC cells. D. Protein concentrations in mg/mL (miR-29a mut: n = 4, p = 0.162; Stx-1a: n = 4, p 
= 0.010; PDHxUTR: n = 2, p = 0.311; R luc only: n = 4, p = 0.566). 
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affected by the FF luciferase reporter vectors, a transfection was conducted with pRL-SV40 and the fill 
plasmid only (Figure 18.B). This showed a significant decrease in RR luciferase activity when transfecting the 
miR-29a OE cells compared to the NTC cells with pRL-SV40 only (p < 0.001, 64.5%), thus the normalization 
factors seem to be affected by the cell lines and when pRL-SV40 is transfected alone, the influence of the 
cell line is greater. This unexpected difference will be further discussed in section 10.  
FF luciferase activities normalized for protein concentrations were decreased in the miR-29a OE cells 
compared to their NTC counterparts with 33.7% for miR-29a mut (p = 0.007), 32.2% for Stx-1a (p = 0.043) 
and 30.1% for PDHxUTR (p = 0.0417) (Figure 18.C). The significant reduction is likely to reflect that the cell 
lines have different growth rates. The protein concentrations of the samples (Figure 18.D) follow the 
pattern of the first transfection (Figure 17.D), where there is more protein in the miR-29a OE cell lines than 
in the corresponding NTC cell lines. There is a non-significant increase in protein concentration of 10.3%, 
29.7% and 17.9% from the miR-29a OE cells to the NTC cells for miR-29a-mut (p = 0.162), PDHxUTR (p = 
0.311) and R luc only (p = 0.566) respectively, while a significant increase of 24.5% is seen for stx-1a (n = 4, 
p = 0.010). 
 
In Figure 19, the β-galactosidase activities and protein concentrations are shown for NTC and miR-29a OE 
cell lines which were transfected with pCMV-LacZ alone and pCMV-LacZ co-transfected with pGL4.23-stx-
1a. This experiment was conducted to investigate whether the differences in β-galactosidase activities 
between the two cell lines were dependent on the reporter vectors and not only the cell line.  
 
 
 
 
 
 
 
 
 
 
β-galactosidase activities decreased 70,9 % and 64,8 % between the NTC cell line and the miR-29a OE cell 
line for stx-1a (p < 0.001) and LacZ only (p < 0.001), respectively. This supports the idea that β-galactosidase 
activities are in fact dependent on the cell lines they are expressed in.  Since the reduction of β-
galactosidase activities between the NTC and miR-29a OE cell lines is similar for both transfections, they 
presumably occur because of a bias in the system. In addition, the β-galactosidase activities are much 
higher for the cells transfected with pCMV-LacZ together with stx-1a than with pCMV-LacZ alone. This was 
unusual, as the normalization vector was expected to have a higher β-galactosidase activity without a 
reporter vector. The protein concentrations show a significant increase in miR-29a OE compared to NTC cell 
lines transfected with stx-1a (41.9%, p < 0.001). pCMV-LacZ alone has a non-significant increase (46.0%, p = 
0.179) due to the size of the error bars, while the relative increase for both transfections are somewhat 
similar. 
Figure 19 β-galactosidase and protein concentrations from transfection 2. A.β-ga lactosidase activi ties for pCMV-LacZ co-
transfected with stx-1a and β-galactosidase activities for pCMV-LacZ transfected without FF luciferase reporter vectors (LacZ only) 
(stx-1a: n = 4, p < 0.001; LacZ only: n = 4, p < 0.001). B. Protein concentrations in mg/mL (stx-1a: n = 4, p < 0.001; LacZ only: n = 4, p = 
0.179). 
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9.2.3 Transfection 3 
This transfection was conducted with the purpose to diminish the difference in normalization protein 
activity between the two cell lines. The difference could occur by the influence of too many of the same 
promoters or promoters employ the same transcription factors and thus, by adding a smaller amount of the 
pRL-SV40 vector, the difference could possibly be minimized. The transfection was conducted using 
pGL4.23 miR-29a per instead of pGL4.23 stx-1a. The results are presented in Figure 20. Transfections with 
miR-29a mut produced FF luciferase counts for both the NTC and miR-29a OE cells which are in the same 
range as the background FF luciferase counts and thus, the transfections with miR-29a mut are excluded 
from the interpretation of the results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the normalized FF luciferase activities (Figure 20.A) a 59.7% decrease from the NTC to miR-29a OE cell 
line with miR-29a per (p < 0.001) and a 22.7% decrease from the NTC to miR-29a OE cell line with PDHxUTR 
(p < 0.001) is observed. The results point toward lowered FF luciferase activity due to miR-29a binding. 
However, the reduction in normalized FF luciferase activity cannot with certainty be attributed to the 
binding of miR-29a to miR-29a per and PDHxUTR because there is a significant reduction of 41.9% and 
44.3% in RR luciferase activity between the cell lines of miR-29a per (p = 0.015) and PDHxUTR (p = 0.012), 
respectively (Figure 20.B). Additionally, a significant reduction of 44.0% is observed in RR luciferase 
activities between the NTC and miR-29a OE cell lines transfected with pRL-SV40 only (p = 0.043), which 
reflects that the lowering of pRL-SV40 concentrations did not result in a lower difference in RR luciferase 
activities between the two cell lines. 
Figure 20 Renilla activities and protein concentrations of Transfection 3 A. FF luci ferase activi ties  normal ized for the Reni l la  
activi ties (miR-29a per: n = 4, p < 0.001; PDHxUTR: n = 4, p < 0.001). B. Reni lla activi ties (miR-29a per: n = 4, p = 0.015; PDHxUTR: n = 
4, p = 0.012; R luc only: n = 4, p = 0.043). C. FF luci ferase activity normalized for protein concentrations relative to the two NTC cel l  
l ines (miR-29a per: n = 4, p = 0.004; PDHxUTR: n = 4, p = 0.004). D. The protein concentration in mg/mL (miR-29a per: n = 4, p = 
0.879; PDHxUTR: n = 4, p = 0.124; R luc only: n = 4, p = 0.579). 
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There is thus no relative difference in RR luciferase activities between cell lines co-transfected with reporter 
vectors and cells transfected with pRL-SV40 alone. This implies that the lowered RR luciferase activities 
between NTC and miR-29a OE cells are indeed caused by the type of cell line and not by binding of miR-29a 
to the FF luciferase reporter vectors. It is additionally worth noting that the RR luciferase activities differ a 
lot between the different transfected vectors (Figure 20.B). 
These data differ from transfection 2, where the luciferase activity of the transfected NTC cells with pRL-
SV40 only was the double amount of the luciferase activity of pRL-SV40 transfected alone in miR-29a OE 
cells. A repetition of the experiment must therefore be performed to minimize errors and to optimize the 
reliability of any possible conclusions.  
The protein measurements for transfection 3 were measured in duplicates. When the difference between 
the duplicates exceeded 40%, the sample that deviated most from the average of the pooled protein 
concentrations was removed. FF luciferase activities are normalized to protein concentrations ( Figure 20.C) 
which show a significant reduction of 74.1% and 70% between the NTC cell line and the miR-29a OE cell line 
for miR-29a per (p = 0.004) and PDHxUTR (p = 0.004), respectively. These results follow the expectations for 
the experiment. However, because there is no comparison to miR-29a mut, it is not possible to determine if 
the reductions are in fact due to binding of miR-29a to its targets or if there still exists a bias in the system. 
When comparing protein concentrations, there is no significant difference between the NTC and miR-29a 
OE cell lines (miR-29a per: p = 0.879; PDHxUTR: p = 0.124) (Figure 20.D), which validates protein 
concentrations as a normalization factor of FF luciferase activity. This can possibly be due to the lower 
concentration of pRL-SV40, which is the only factor changed between transfection 2 and 3.  
 
The transfections with pCMV-LacZ only and pCMV-LacZ co-transfected with miR-29a per are shown in 
Figure 21.  
  
 
Data show a non-significant reduction in β-galactosidase activity of 10.7% between the NTC and miR-29a 
OE cell line when pCMV-LacZ was transfected alone (p = 0.297) (Figure 21.A) and a non-significant increase 
in β-galactosidase activity between the NTC and miR-29a OE cell line of 4.7% when pCMV-LacZ was co-
transfected with miR-29a per (p = 0.406). The results in this transfection indicate that there is no significant 
difference between the two cell lines when transfecting with miR-29a per and pCMV-LacZ or pCMV-LacZ 
only which indicates that the assay is functioning. The FF luciferase levels in LacZ-only reflects a background 
activity, as luciferase is not incorporated in the vector. Since miR-29a OE cell lines transfected with miR-29a 
Figure 21 β-galactosidase activities and protein concentrations of transfection 3. A. β-ga lactosidase activities  for pCMV-LacZ 
contransfected with miR-29a perfect and β-galactosidase activities for pCMV-LacZ transfected a lone (miR-29a per: n = 4, p = 
0.406; LacZ only: n = 4, p = 0.297). B. Protein concentrations  in mg/mL (miR-29a per: n = 4, p = 0.727; LacZ only: n = 4, p = 
0.525). 
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per show similar raw FF luciferase activities to both cell lines transfected with LacZ only (Appendix 13.6 
Figure III), the data cannot be trusted. 
 
9.2.4 Transfection 4 
INS-1E cells were transfected with the same set of vectors as the previous transfections but to simulate the 
over-expression and normal levels of miR-29a, oligos of miR-29a mimic and a negative mimic were added 
exogenously. All the cell lines showed FF luciferase levels that were higher than the background FF 
luciferase activity and therefore the transfection was succesful. The luciferase levels were greatly increased 
in the cell lines transfected with miR-29a mut compared to cells expressing miR-29a per and PDHxUTR 
(Appendix 13.6 Figure IV). Furthermore, there was a non-significant increase in FF luciferase activity 
between the negative and the positive mimic cell line for miR-29a mut (p = 0.051). The experiment will 
have to be repeated to establish if these trends are a consequence of the system.  
 
The results show the expected activities for miR-29a per; a low activity in mimic negative and even lower in 
mimic positive. The luciferase activities of PDHxUTR are lower in the miR-29a positive mimic cells, 
compared to the negative cells. However, the decrease is insignificant and may be due to randomness 
rather than a binding of miR-29a to PDHxUTR. FF luciferase activities normalized to RR luciferase activities 
(Figure 22.A) show no significant difference between negative and positive miR-29a mimics for mut (p = 
0.277). There is a decrease in normalized FF luciferase activity from the negative to the positive mimic of 
miR-29a per of 68.4% (p = 0.078). However, the reduction is not significant but since we expect this 
transient mimic system to show a greater variance between the samples, and since the p-value is not far 
from the α-significance level, it is possible that the effect seen in miR-29a per is caused by a binding to miR-
29a. It is additionally remarkable that PDHxUTR shows a significant reduction between miR-29a positive 
and negative mimics (49.6%, p < 0.001), which could reflect that miR-29a binds to PDHxUTR. The RR 
luciferase activities show discrepancy between the different samples (Figure 22.B), but not consistently 
throughout the different transfections which might reflect pure differences in transfection success rates 
rather than a bias in the system.  
41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The FF luciferase activity normalized to protein concentrations show a higher FF luciferase activity of the 
mimic positive miR-29a mut, compared to the mimic negative (p = 0.068) (Figure 22.C) which is inconsistent 
with the expected results. These results thus imply higher FF luciferase activities when miR-29a is over-
expressed in cells with miR-29a mut. MiR-29a per and PDHxUTR show non-significantly lower FF luciferase 
activities in the mimic positive compared to the mimic negative (miR-29a per: p = 0.179; PDHxUTR p = 
0.464). Protein concentrations show no significant difference between the samples ( miR-29a mut: p = 
0.290; miR-29a per: p = 0.823; PDHxUTR: p = 0.651) and thus the cells express similar growth rates. 
  
Figure 22 The mimic transfection. A. FF luci ferase activities normalized to RR luciferase activities (miR-29a mut: n = 4, p = 0.277; 
miR-29a per: n = 4, p = 0.078; PDHxUTR: n = 4, p < 0.001). B. Renilla activities (miR-29a mut: n = 4, p = 0.032; miR-29a per: n = 4, p 
= 0.035; PDHxUTR: n = 4, p < 0.001). C. FF luci ferase activity normalized for protein concentrations relative to the negative mimics  
(miR-29a mut: n = 4, p = 0.047; miR-29a per: n = 4, p = 0.155; PDHxUTR: n = 4, p = 0.464). D. Protein concentrations  in mg/mL 
(miR-29a mut: n = 4, p = 0.290; miR-29a per: n = 4, p = 0.823; PDHxUTR: n = 4, p = 0.648). A and C have two y-axes : Mir-29a mut 
refers  to the left axis  whi le miR-29a per and PDHxUTR refers  to the right axis . 
42 
 
10 Discussion 
MiR-29a is interesting to examine in regards to the pathogenesis of diabetes because it is seen up-
regulated in response to hyperglycemia and diabetes (He et al., 2007; Herrera et al., 2010) and because 
over-expression of miR-29a decreases GSIS (Bagge et al., 2012). PDHxUTR is a predicted target of miR-29a 
(MicroRNA.org, 2010; TargetScan.org, 2012) which suggests that miR-29a might have a down-regulating 
effect on the PDC activity. A lowered PDC activity is seen in diabetes consistent with the hypothesis that 
miR-29a is up-regulated in diabetes and results in down-regulated PDC activity. 
 
10.1 Mutagenesis 
During this project, mutagenesis of the predicted target site for miR-29a in PDHxUTR was attempted by 
performance of overlap-extension PCR and whole plasmid PCR, both performed on the pMirTarget 
PDHxUTR vector. 
 
10.2 Overlap-extension PCR 
Several steps of the overlap-extension PCR were successful, since the gels (Figure 15) showed the expected 
fragments. The subsequent digestions and ligations did not yield any transformed cells and the possible 
optimizations will therefore be discussed. If the digestion of pMirTarget had been incomplete and only one 
or none of the restriction enzymes had worked, colonies would have appeared on the negative control 
plates of the subsequent transformations. As the negative control plates had no colonies 4 out of 5 times, 
we can conclude that the digestions of the vector were successful. It is not possible to test if the insert was 
digested successfully, since the digestion only discards 18bp and no difference could have been seen in a 
fragment analysis. The ligation did not contain a positive control, which means that it cannot with certainty 
be determined whether it was the ligation or the digestion that was unsuccessful.  
 
The ligations were optimized by changing the vector-insert ratio (Table 7 and Table 14) as the correct ratio 
is critical for ligation. A DNA concentration that is too high may favour intermolecular ligation of multiple 
inserts and vectors, resulting in large products when run on a gel and poor transformation yields. Two 
different ratios were tested without any effect on the results. Thus, it is certain that the vector-insert ratio 
cannot be the cause of the lack of successfully transformed bacteria. Only one successfully ligated vector 
needs to enter a bacterium in order to produce a colony with the desired insert. It is therefore unlikely that 
a fault in the ligation can account for a lack of colonies. It is thus more likely that the digestion of the insert 
is the reason for the lack of colonies on the plates. The digestion worked when conducted with the 
pMirTarget PDHxUTR vector (Figure 16) and thus it is certain that the restriction enzymes are functioning. A 
possible explanation for the malfunctioning digestion of the PDHxUTR mut insert could be that there were 
not enough nucleotides at the end of each restriction site for the enzymes to work properly . However, prior 
to designing the primers, the number of nucleotides needed between the restriction site and the end of the 
fragment for digestion was considered to be sufficient. EcoRI cuts with 50-100% efficiency with 5bp to the 
end, while MluI cuts with 50-100% efficiency with 3bp to the end (New England Biolabs, 2014a). The 
fragment from the overlap-extension PCR has 12nt between the EcoRI restriction site and the end and 6nt 
between MluI restriction site and the end. However, an unsuccessful digestion should still be considered as 
a possible reason for the ineffective mutagenesis. To test whether the enzymes can digest fragments with 
longer sequences at the ends, primers could be designed that were complementary further away from the 
restriction sites at both ends of the insert.  
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Another approach could be the use of a TOPO® TA Cloning® Kit, which is a cloning strategy where the 
sequence of interest is amplified by PCR using Taq polymerase. Taq polymerase has a transferase activity 
that adds a single deoxyadenosine (A) to the 3´ ends of PCR products. A linearized vector with blunt-ends is 
tailed with a deoxythymidine (T) by terminal transferase, leaving the ends with a single 3’ -overhang. The 
amplified sequence can be cloned into the vector without the requirement of DNA ligases, but relying on 
the ability of A and T to hybridize. The insert of the hybridized vector is then sub-cloned into the pMirTarget 
reporter vector. Overlap-extension PCR may thus, with the right alterations in the method, be employed as 
a functional approach to introducing a mutation. 
 
10.3 Whole plasmid PCR 
As described in section 9.1.2, none of the attempted whole plasmid PCRs were successful. In fact, they did 
not show any amplified DNA. The explanation is most likely to be the low melting temperature for the 
primers used (primers 2F and 1R). Since the primers introduce a mutation, they have a wobble sequence 
which means that only the 3’ end of the primer can anneal to the template DNA. For replication to initiate, 
the only sequence able to anneal is the region upstream of the mutation, which constitutes 20bp for both 
primers. As the sequences contain a high amount of  A and T nucleotides, the melting temperature for both 
primers is only 47°C (New England Biolabs, 2014b). This means that the annealing temperature preferably 
should be lower than 47°C. In table Table 9 it shows that only one annealing temperature below 47°C was 
tested. Even with an annealing temperature of 46°C the gels did not show any bands except for primers, 
which means that the binding between the primers and the DNA template might not have been stable 
enough for initiation of elongation. It is worth mentioning that an annealing temperature several d egrees 
above optimum decreases the chance of the primer binding but should not make it impossible. 
Theoretically, only one set of primers have to anneal in the first reaction in order to produce a strand fully 
complementary to the primers for further exponential amplification. This is a reason to consider whether it 
might be the primers or the fact that they are reverse complimentary to each other and therefore have a 
risk of producing primer dimers that could be the reason why the PCR did not work. Another consideration 
is the lengths of the cycles used for PCR. If the elongation time is not long enough for the replication to be 
completed, the reverse primer will not be able to anneal, which in turn results in linear amplification and a 
DNA yield too low for detection on a gel. To avoid this, new primers could be designed that contained 
longer sequences at the 3’ end. This would increase the stability with which the primers bind to the target 
DNA. An increased annealing temperature would also reduce the risk of unspecific binding, which is a 
problem connected with low annealing temperatures. 
 
10.4 Luciferase reporter gene analysis 
The experiments resulted in successful transfections with pMirTarget PDHxUTR in addition to two different 
normalization vectors; pCMV-LacZ and pRL-SV40. This makes it possible to compare transfection success 
rates and discuss the reliability of the different normalization vectors. Two different cell systems were set 
up in order to optimize the reliability of the results and to conclude on the possible binding site for miR-29a 
in PDHxUTR.  
 
10.4.1 Transfections with pCMV-LacZ 
The FF luciferase activities normalized for β-galactosidase activities are shown in Figure 17.A. The results 
suggest that an over-expression of miR-29a has no effect on the expression of reporter vectors, which is 
44 
 
inconsistent with the results from a previous study, reporting miR-29a as a target of stx-1a (Bagge et al., 
2013). There exists a significant reduction in β-galactosidase activities between the NTC and miR-29a OE 
cell lines (miR-29a mut: p < 0.001; Stx-1a: p = 0.002; PDHxUTR: p < 0.001) which suggests a biased system 
and the ineffectivity of using pCMV-LacZ as a normalization vector. Normalization factors are important in 
validating the results of the experiments and the advantage of co-transfecting normalization vectors 
together with reporter vectors is that the transfection success rate is taken into account. Total protein 
concentrations reflect cell growth and is an alternative normalization factor, which includes all cells, both 
transfected and non-transfected. Normalization factors are in general expected to be somewhat equal 
throughout the different samples and when the normalization factor differentiates between samples, it 
must be considered whether the differences seen is caused by a difference in transfection success rates or 
if there is a factor in the system that is affecting the results.  
 
Transcription factors and protein synthesis 
The first two transfections show a significant reduction in β-galactosidase activity between the NTC and the 
miR-29a OE cell lines of around 60% for all samples (Figure 17.B and Figure 19.A). This supports the fact 
that a bias exists in the system and renders β-galactosidase unsuitable as a normalization factor for the 
experiments. The bias can be explained by several mechanisms, one of which is the competition for 
transcription factors. The cells contain several strong promoters that require simultaneous and contiuous 
activation. The miRNA over-expression in both the NTC and the miR-29a cells lines is driven by a CMV 
promoter and so is LacZ in pCMV-LacZ. Apart from these strong viral promoters, an SV40 promoter drives 
transscription of stx-1a, miR-29a mut, miR-29a per and PDHxUTR. Because the CMV and the SV40 
promoters are both strong viral promoters (Promega, 2014) a competition for transcription factors might 
occur between the same type of promoter but also between the different promoters if overlapp ing 
transcription factors exist. In transfection 1, the protein concentrations of miR-29a OE cells are significantly 
higher than for NTC cells in miR-29a mut (p = 0.008) and stx-1a (p = 0.014) (Figure 17.D). This could be 
explained by the miR-29a OE cells having higher growth rates, which in turn would mean that they direct 
the transcription factors towards cell division instead of transcribing the reporter genes, which are non-
essential for division. The protein concentration is however only skewed between the cell lines in 
transfection 1 and 2 (Figure 17.D, Figure 18.D and Figure 19.B), while protein concentrations in transfection 
3 and the transfection with mimics are more similar between the cell lines (Figure 20.D, Figure 21.B and 
Figure 22.D). This could indicate that the measurements were carried out with greater accuracy as the 
experiment progressed.  
 
Another hypothesis concerning the difference in protein concentrations could be that miR-29a up-regulates 
protein synthesis. An up-regulation of protein synthesis by miR-29a would most likely affect several events 
in the cell and therefore also up-regulate the synthesis of β-galactosidase and RR luciferase. Lower activities 
of both β-galactosidase and RR luciferase were observed in transfection 1 and 2. Only single measurements 
were prepared when measuring the protein concentrations of transfection 1 and 2 while a double or triple 
measurement is preferred to increase accuracy. Duplicates of protein measurements were prepared in 
transfection 3 and 4, which yielded similar protein concentrations (see error bars in Figure 20.D and Figure 
22.D). This suggests that the lack of duplicates in the first two transfections could have had an influence on 
the results. Conversely, the standard curve shows low discrepancy (Appendix 13.7) and hence, it is difficult 
to determine the reason for variance in protein concentrations. A re-measuring of the samples would be 
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ideal, but due to time limitations, this was not possible.  Replications of the experiment would clarify if 
differences in protein concentrations occur between the cell lines.  
 
The competition for transcription factors is still  a reasonable explanation for the differences observed 
between cell lines in protein levels. One of the ways to reduce the influence of a competition is to reduce 
the amount of vector added to the samples, which would diminish the risk of depleting the cells of 
transcription factors. The pCMV-LacZ concentration was lowered accordingly to one tenth of the original 
concentration in transfection 3. The β-galactosidase counts were in the range of 400,000 to 1,600,000 
counts before the amount of pCMV-LacZ was reduced (Figure 17.B and Figure 19.A). After the reduction, 
the β-galactosidase counts did not exceed 30,000 in addition to showing a more consistent distribution. 
This argues that the differences in β-galactosidase activity between the cell lines in transfection 1 and 2 
were indeed caused by a competition for transcription factors.  
  
A possible miR-29a target in pCMV-LacZ 
The reduction of β-galactosidase actitivy could also be sought in the possiblity of pCMV-LacZ having a target 
site for miR-29a. A target site was indeed found using BLAST align (Appendix 13.8). This means that the 
decrease in β-galactosidase activity could be explained by miR-29a exercising a regulatory effect on the 
mRNA for LacZ. It is reasonable to believe that the regulation is caused due to the considerable amount of 
LacZ mRNA present in the cells. Indeed, when the β-galactosidase counts were lower (transfection 3, Figure 
21.A), there was no difference in β-galactosidase activity between the different cell lines.   
If an interaction between β-galactosidase and miR-29a exists, it follows that miR-29a is prohibited from 
binding to PDHxUTR, stx-1a and miR-29a per because the regulation of miR-29a is exercised on the 
normalization vector. The purpose of miR-29a in this experimental setup is to regulate translation of 
reporter genes. If miR-29a cannot regulate the target genes as intended, the FF luciferase levels are not 
expected to be an accurate representation of the reality.  
 
Transfection success 
Whether the reduction of β-galactosidase activity is caused by a competition for transcription factors or by 
a binding of miR-29a, it is certain that the system needs to be optimized to yield applicable results. It is also 
a possibility that the difference is caused by a difference in transfection success rate. This could be tested 
by utilizing the RFP gene on pMirTarget to co-localize the cells successfully transfected with pMirTarget 
with those transfected with pCMV-LacZ. This would allow for quantification of successfully transfected cells 
and to determine if the reason for the difference in β-galactosidase activity could be explained by the 
transfection success or if the bias should be sought in the nature of the cell lines. 
Regardless of the reason for the bias in the system, a reduction of the pCMV-LacZ concentration seems to 
be a feasible solution. More replications of the experiment would have to be performed to confirm it.  
 
10.4.2 Transfections with pRL-SV40  
The pRL-SV40 vector was utilized for transfection 2, 3 and the transfection with mimic oligos. When RR 
luciferase activity is used as a normalization factor, the FF luci ferase activities do not follow the expected 
trends (Figure 18.A). The sample expressing miR-29a mut shows a decrease in normalized FF luciferase 
activity from the NTC to miR-29a OE cell lines while the sample expressing stx-1a shows an increase. These 
data are in contrary to the expected results. The RR luciferase raw data show a consistent 30% decrease in 
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normalization factor between all NTC and miR-29a OE cell lines (Figure 18.B). This is markedly lower than 
the normalization for β-galactosidase, which had a consistent 60% decrease. A BLAST alignment of miR-29a 
target sites in pRL-SV40 showed no hits and thus the reduction in RR luciferase activities cannot be 
attributed to a down-regulation by miR-29a. 
  
In transfection 3 the FF luciferase activity normalized for both RR luciferase and protein concentration 
shows the expected distributions (Figure 20.A and C); miR-29a per has a significant decrease in FF luciferase 
activity between the NTC and the miR-29a OE cell line normalized for RR luciferase (p < 0.001) and for 
protein levels (p = 0.004). Because the miR-29a mut sample could not be included in the analysis of the 
results, it cannot be compared to the results for miR-29a per, and thus it cannot with certainty be 
determined that the reduction in normalized FF luciferase in pMirTarget PDHxUTR is in fact due to miR-29a 
over-expression, but it is an encouraging result. Since a reduction is also seen between the miR-29a OE cell 
line transfected with pMirTarget PDHxUTR, the results are an indication of a potential binding, although the 
experiment would have to be replicated for the result to be accurate. That the protein concentrations 
(Figure 20.D) do not show a systematic difference between the cell lines, supports the reliability of the 
data. 
 
Transfection 3 was normalized to the RR luciferase activity. It is a possibility that a competition for 
transfection factors occurs due to the SV40 promoter in pRL-SV40. The concentration of pRL-SV40 was 
decreased in transfection 3, where only a fifth of the original conce ntration of pRL-SV40 was used, in order 
to reduce the effect of the bias. The difference in RR luciferase activities between the cell lines did however 
not diminish when a smaller amount of pRL-SV40 was added (Figure 18.B and Figure 20.B), as was 
expected. The difference in FF luciferase raw data between the NTC and the miR-29a OE cell lines is 
approximately 40% (Appendix 13.6 Figure III), but as the normalization shows the expected results for the 
control, miR-29a per, the difference in RR luciferase activity can be a result of different transfection success 
rates.  
 
RR luciferase activities in transfection 2 show that the normalization vectors transfected alone yields a 
lower activity of their respective normalization factors in the miR-29a OE cells than when co-transfected 
with a reporter vector (Figure 18.B and Figure 19.B). When a normalization vector is transfected without a 
reporter vector the luciferase activity is expected to increase because of a lack of transcription factor 
competition. In this case the opposite is observed. The NTC cell line has a higher activity than the miR-29a 
OE cell line, regardless of which plasmids are added.   
 
If the reductions in RR luciferase and β-galactosidase are caused by competition for transcription factors, 
the low activity of the normalization factor, when the normalization vector was transfected alone, was 
unexpected. When fewer promoters are competing, more products should be produced. This could indicate 
that the bias in the system when using pRL-SV40, is not caused by competition between the promoters. 
 
It is interesting to note that the differences in normalization factor levels do not only occur between the 
NTC and miR-29a OE cell lines but also between NTC cell lines (Figure 17Figure 17.B, Figure 19.A, Figure 
21.B and Figure 22.B). This could be caused by either different transfection success rates or by a difference 
in expression of normalization proteins. An assumption in the experiment is that the cells are transfected in 
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the same ratio of normalization to reporter plasmid in each sample, but if normalization factors varies 
between the NTC cell lines, this might not be the case. 
 
10.4.3 Transfections with mimic oligos  
In the mimic experiment, the FF luciferase activity normalized for RR luciferase activity show expected 
values for miR-29a mut and miR-29a per since the activity of miR-29a per is 70% lower in the miR-29a OE 
cell line compared to the NTC (p = 0.078) and in the miR-29a mut, the activities are similar (p = 0.277). 
PDHxUTR shows a 50% decrease in normalized FF luciferase activity from the NTC to the miR-29a OE cell 
line (p < 0.001). RR luciferase activities are higher in positive cell lines compared to their negative 
counterparts but since the transfected control vectors behave as expected, it implies that the difference 
seen in RR luciferase activities between the negative and positive cell lines could be due to a difference in 
transfection success rate. Further, since the increase in β-galactosidase activities from negative to positive 
cell lines is not consistent between the different transfections, it implies that the difference is in fact due to 
randomness in transfection success rate rather than a bias in the system. This argument is further 
supported by the results of protein concentrations, which show no significant difference between cell lines 
and thus indicate similar growth rates of the cells. This suggests that the normalization for protein is not 
efficient, since transfection success rates varies between cells and is not taken into account in the protein 
measurements. The data in Figure 22.A suggest that PDHxUTR is indeed down-regulated by an over-
expression of miR-29a and thus, PDHxUTR could be a target of miR-29a. If miR-29a is a regulator of E3BP it 
would imply, that the over-expression of miR-29a could be related to the dysregulation of glucose 
homeostasis by inhibiting the function of PDC. Since the results are only obtained once, future replications 
of the experiment would be important to determine the effect of miR-29a on PDHx and other experiments 
might be set up to examine the influence of miR-29a binding to PDHxUTR in the onset and maintenance of 
diabetes. 
 
The results from the mimic transfections are more variable than those of the constitutive method because 
miR-29a is added as an exogenous substrate rather than the endogenous constitutive expression that 
prevails in the miR-29a OE cell lines, which raise the need for replications of the experiment. Additionally, 
when adding ds-siRNA mimic oligos exogenously, it is possible that much higher levels of the miRNA exists 
in the cytoplasm compared to a system where the cells themselves have to synthesize the miRNA since the 
oligos only have to penetrate the plasma membrane to be distributed in RISC complexes in the cytoplasm.  
This effect is noteworthy when comparing the two systems used since higher levels of miR-29a might 
increase miRNA binding to targets. However, when comparing the effects of PDHxUTR to the controls, we 
see that the controls behave as predicted and thus, we might after all rely on the down -regulation of 
PDHxUTR seen in the positive mimic system. As it was planned in this experiment, it would be desirable to 
compare the effects of the wild type PDHxUTR with the results of a mutated PDHxUTR with a scrambled 
binding site to see the effects of a miR-29a over-expression as an addition to the control vectors that were 
included. 
 
Secondary structures of mRNA UTRs might be of significance in binding of a miRNA to a target. Thus, when 
we investigate the UTR of PDHx without PDHx itself included, this might be a limitation of the system and it 
could change the binding affinity of miR-29a.  
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The regulation of PDHx by miR-29a could further be confirmed by a RT-qPCR analysis of β-cells with the NTC 
cell line or miR-29a OE cell line. If the over-expression of miR-29a results in significant lower mRNA and 
protein levels of PDHx, then PDHxUTR must be a target of miR-29a. Since miRNAs function by either 
degrading target mRNA by cleavage or repressing translation by storage of mRNA, lower mRNA levels of 
PDHx might not be seen if miR-29a functions by storing mRNA rather than degrading it. Thus, a comparison 
of PDHx mRNA and protein levels in relation to miR-29a levels added, would clarify which method is 
employed by miR-29a. Additionally, the function of PDC could be investigated in cell lines expressing 
normal and elevated levels of miR-29a by measuring ATP-levels or TCA cycle intermediates, to see if miR-
29a has an effect on their relative concentrations. In this way it could be  shown how miR-29a affects PDC 
function and not just PDHx translation.  
 
11 Conclusion 
The constitutive endogenous miR-29a producing system provided data suggesting that the activity of -
galactosidase and RR luciferase are dependent on the cell lines they are expressed in. This might be due to 
increased growth rate of miR-29a OE cells compared to NTC cells resulting in reduced availability of 
transcription factors needed for transcription of normalization factors or a competition for transcription 
factors internally between the reporter vector promoters and the normalization vector promoters.  
BLAST alignment predicts pCMV-LacZ to be a partial target of miR-29a indicating that lower levels of -
galactosidase can be caused by miR-29a regulating the expression levels. A smaller amount of added pCMV-
LacZ equalizes -galactosidase activity between NTC cells and miR-29a OE cells and between the different 
NTC cell lines. This is not observed for pRL-SV40, which can indicate that the reason for the difference in 
normalization factor may be caused by different mechanisms for the two normalization vectors.  
The mimic strategy is determined to be superior compared to the endogenous miR-29a system for this 
experiment since a bias in normalization factors undermines the data analysis for the endogenous 
constitutive strategy. The mimic strategy yields reasonable values for FF luciferase normalized to RR 
luciferase and thus the data are reliable. The analysis indicates that PDHxUTR is a target for miR-29a, which 
further can be confirmed by incorporating a mutated version of PDHxUTR and repeating the experiment. 
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13 Appendices 
 
13.1 PDHxUTR sequence 
Swquence of PDHxUTR in pMirTarget (Origene, 2014). Grey is a part of the luciferase gene, placed 
upstream to PDHxUTR. Red is marking the insertion sites of PDHxUTR (restriction sites for AsiSI and MluI). 
Orange is a fragment of the PDHx gene, followed by a stop codon in blue. The green part constitutes the 
proposed binding site for miR-29a (In mutant; this sequence is altered). Underlined sequences constitute 
sites where the used primers will anneal. EcoRI restriction site is marked by yellow and MluI restriction site 
is marked by blue. 
 
 
Wild type 
CAATTGGCAGAGCTCAGAATTCAAGCGATCGCTCCTATCCGACTTGCCTAGTCCTCAAAGATAAGAAGTTGGTGTTCA
GCTTAGTTGATTCAGTAGTTGTTACCAAGAAACATATGTTATAGGAAAACAACTTGGTATTTAAGTATGAAGTGGATG
AAATGTTTATTTATTTAAGGTGAAAGCATTTGACCCAGGGTGTCTTCATCTTCAATTTGGGTTTAATGTTATAGAAATAA
ATGATGATAAACTCTAACTAATAAAGGAAAGAGAATATTTGGTTACTCAGATCCATTTTTAACCTCTGGTGCTGTATAA
AGGGAATATTAAACTAGATGTAAATCAAAGTATATGTTTGGCTCATTTGAGCATTTTGGAATATTTGAGAATGTATGAT
ACATGTAAAATTAAAAAAACTATTAGAACTGTACCATAATTATGTTGAAGGTAGAAGTGATCTTCAAAGAGATGGCCA
TTAACTTAGCAGTGGGACCTCACTTTTACAAGCACTGCTCTAGATATACTTGAAGAATTTAATAGGTACAGAAGTTTAT
TCTGGATAATAAATAAATAAGGATCACACTGTATTAGGGGTTATGGCAACATTATTGAATTTTTTATGTACATAAAGCC
ATATGTTTAGGGTGGTTTCTATCTGTCTTGTTTTTCACTTATATAACACTGTGAACTTCTAAAGCAAGAGGATAAAAGA
AGCATGAATGAAAAGAATGACATTTCAAAAAAATGGTTCAATGAAAAACTATAGCTAAAATATGTAAACCTTTCTAGG
TAAACCGCTTGCCTTCATCTTGAGTCGGAATATATTTAAATAAATTGTGTTATCTCTTGCCAAACATTTTGTTAGTGTTTA
TTTAAAAACAAAATGTTGTTTCTTAATGCATTTAAATCAGTTTTGTATTGTGCAGTAAAATGTGAGAAAATATAAACATT
TCTATTGTATTTTAAATGTTAAAACACAAAAGTTCAATAAACCTTGACGCGTAAGCGGCCGCGGCATCTAGATTCGAAG
AAAATGACCG 
 
Mutant 
CAATTGGCAGAGCTCAGAATTCAAGCGATCGCTCCTATCCGACTTGCCTAGTCCTCAAAGATAAGAAGTTGGTGTTCA
GCTTAGTTGATTCAGTAGTTGTTACCAAGAAACATATGTTATAGGAAAACAACTTGGTATTTAAGTATGAAGTGGATG
AAATGTTTATTTATTTAAGGTGAAAGCATTTGACCCAGGGTGTCTTCATCTTCAATTTGGGTTTAATGTTATAGAAATAA
ATGATGATAAACTCTAACTAATAAAGGAAAGAGAATATTTGGTTACTCAGATCCATTTTTAACCTCTAGCGTTGTATAA
AGGGAATATTAAACTAGATGTAAATCAAAGTATATGTTTGGCTCATTTGAGCATTTTGGAATATTTGAGAATGTATGAT
ACATGTAAAATTAAAAAAACTATTAGAACTGTACCATAATTATGTTGAAGGTAGAAGTGATCTTCAAAGAGATGGCCA
TTAACTTAGCAGTGGGACCTCACTTTTACAAGCACTGCTCTAGATATACTTGAAGAATTTAATAGGTACAGAAGTTTAT
TCTGGATAATAAATAAATAAGGATCACACTGTATTAGGGGTTATGGCAACATTATTGAATTTTTTATGTACATAAAGCC
ATATGTTTAGGGTGGTTTCTATCTGTCTTGTTTTTCACTTATATAACACTGTGAACTTCTAAAGCAAGAGGATAAAAGA
AGCATGAATGAAAAGAATGACATTTCAAAAAAATGGTTCAATGAAAAACTATAGCTAAAATATGTAAACCTTTCTAGG
TAAACCGCTTGCCTTCATCTTGAGTCGGAATATATTTAAATAAATTGTGTTATCTCTTGCCAAACATTTTGTTAGTGTTTA
TTTAAAAACAAAATGTTGTTTCTTAATGCATTTAAATCAGTTTTGTATTGTGCAGTAAAATGTGAGAAAATATAAACATT
TCTATTGTATTTTAAATGTTAAAACACAAAAGTTCAATAAACCTTGACGCGTAAGCGGCCGCGGCATCTAGATTCGAAG
AAAATGACCG 
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13.2 Transfection 1 
Data – Figure 17 
  FF luc bgal FF luc/bgal Protein conc. FF luc/Protein conc. 
Stx-1a NTC 19379 912755 0,02123133 0,571998 33879,48909 
  18505 964498 0,01918615 0,4970935 37226,39705 
  25101 1334158 0,01881411 0,476665 52659,62468 
  21255 1107333 0,01919477 0,54476 39017,18188 
 miR-29a OE 13368 663697 0,02014172 0,721807 18520,18614 
  6124 360317 0,01699615 1,0282345 5955,83984 
  9300 368913 0,0252092 1,048663 8868,435331 
  8575 416261 0,02060006 1,0690915 8020,8289 
Mut NTC 36443 1465752 0,02486301 0,531141 68612,66594 
  23937 1166672 0,02051733 0,5243315 45652,41646 
  33917 1299861 0,02609279 0,749045 45280,32361 
  27666 1305399 0,02119352 0,531141 52087,86367 
 miR-29a OE 9560 425723 0,02245592 0,762664 12535,00886 
  10577 484014 0,02185267 1,0418535 10152,09912 
  9971 391702 0,02545558 1,1371865 8768,130821 
  10100 573805 0,0176018 1,266567 7974,311663 
PDHX UTR NTC 2798 830036 0,00337094 0,762664 3668,719121 
  2702 846510 0,00319193 1,1099485 2434,347179 
  1981 685789 0,00288864 1,4095665 1405,396624 
  2483 899378 0,0027608 0,6060455 4097,052119 
 miR-29a OE 757 246873 0,00306635 1,116758 677,8550053 
  773 273509 0,00282623 1,0963295 705,0799965 
  914 348315 0,00262406 1,184853 771,40371 
  680 231568 0,0029365 1,1371865 597,9670001 
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F-test – Figure 17 
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T-test – Figure 17 
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13.3 Transfection 2 
Data – Figure 18 
    FF luc renilla LUC/renilla Protein conc. LUC/protein 
Stx-1a NTC 35099 67205 0,522268 0,863577 40643,74 
    32598 47424 0,687373 0,940071 34676,1 
    34999 46372 0,754744 0,867603 40339,88 
    23886 36359 0,656949 1,016565 23496,78 
  29a OE 30432 32686 0,931041 1,072929 28363,48 
    24512 31483 0,778579 1,060851 23105,98 
    29456 29388 1,002314 1,266177 23263,73 
    23271 40285 0,577659 1,189683 19560,67 
mut NTC 48939 45551 1,074378 0,899811 54388,09 
    48547 36670 1,323889 0,984357 49318,49 
    72738 53044 1,371277 1,068903 68049,21 
    41002 32324 1,268469 1,072929 38215,02 
  29a OE 22056 28330 0,778539 1,121241 19671,06 
    24260 28647 0,84686 0,980331 24746,74 
    17684 26568 0,665613 1,113189 15885,89 
    24295 27637 0,879075 1,225917 19817,82 
pRL-only NTC 68 71677 0,000949 0,895785 75,91107 
    53 62701 0,000845 0,819291 64,69008 
    52 62433 0,000833 2,055273 25,30078 
    53 59501 0,000891 2,566575 20,65009 
  29a OE 50 21779 0,002296 1,225917 40,7858 
    698 17998 0,038782 1,064877 655,4748 
    54 24381 0,002215 1,237995 43,61892 
    60 26890 0,002231 1,676829 35,78182 
pdhx NTC 14846 55205 0,268925 0,964227 15396,79 
    13988 44042 0,317606 0,976305 14327,49 
pdhx 29a OE 5716 36463 0,156762 1,411113 4050,703 
    8458 32330 0,261615 1,105137 7653,35 
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F-test – Figure 18 
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T-test – Figure 18 
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Data – Figure 19 
    LUC Gal Luc/Gal Proteincon LUC/protein 
Stx-1a NTC 13295 1627788 0,008168 0,907863 14644,28 
    17687 1531682 0,011547 0,883707 20014,55 
    21740 1637189 0,013279 0,883707 24600,91 
    17404 1523648 0,011423 0,992409 17537,12 
  29a OE 8065 427958 0,018845 1,310463 6154,313 
    7650 518514 0,014754 1,258125 6080,477 
    5226 431599 0,012108 1,302411 4012,558 
    6840 460410 0,014856 1,213839 5635,014 
lacZ only NTC 56 648364 8,64E-05 0,956175 58,56668 
    59 695452 8,48E-05 1,105137 53,38705 
    105 684433 0,000153 1,390983 75,48618 
    62 602267 0,000103 1,016565 60,98971 
  29a OE 55 223833 0,000246 1,362801 40,35806 
    59 198592 0,000297 1,523841 38,71795 
    163 249161 0,000654 2,502159 65,14374 
    61 255420 0,000239 1,137345 53,63368 
 
F-test for figure 19 
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T-test for figure 19 
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13.4 Transfection 3 
Data – figure 20 
    FF luc RR luc FF luc/RR luc FF luc/protein Protein conc. 
perfect NTC 12604 4612 2,732870772 10766,1002 1,170712 
    11106 3478 3,193214491 13479,88122 0,823895 
    10844 3013 3,599070694 10724,49428 1,011143 
    8386 2799 2,996070025 7464,224283 1,123493 
  OE 2649 2261 1,171605484 2566,088401 1,032311 
    2492 1674 1,48864994 3042,69882 0,81901 
    2174 1855 1,171967655 3569,988776 0,608966 
    2752 2285 1,204376368 1794,223084 1,533812 
mut NTC 85 178 0,47752809 112,7500772 0,75388 
    148 169 0,875739645 181,0660016 0,817382 
    76 150 0,506666667 83,0531655 0,915077 
    102 161 0,633540373 88,48014532 1,152801 
  OE 69 151 0,456953642 59,93887538 1,151173 
    64 158 0,405063291 52,68901257 1,214675 
    76 156 0,487179487 61,65902115 1,232585 
    263 144 1,826388889 180,0703541 1,46054 
pRL-only NTC 54 497 0,108651911   1,450771 
    148 390 0,379487179   1,001374 
    60 276 0,217391304   1,589172 
    50 324 0,154320988   0,713174 
  OE 70 210 0,333333333   0,760393 
    56 193 0,29015544   1,10721 
    55 206 0,266990291   1,475195 
    63 225 0,28   0,797843 
PDHx NTC 3030 2073 1,461649783 3893,08284 0,778304 
    2425 1569 1,545570427 2118,533477 1,14466 
    2323 1649 1,408732565 3380,770359 0,687122 
    1638 1145 1,430567686 2355,94385 0,695263 
  OE 899 728 1,23489011 494,7370217 1,817127 
    963 899 1,071190211 1277,392051 0,75388 
    1128 992 1,137096774 1035,528116 1,089299 
    1045 964 1,084024896 714,6919114 1,462169 
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F-test – figure 20 
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T-test – Figure 20 
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Data – Figure 21 
    FF luc bgal FF luc/bgal Protein conc. FF luc/protein 
perfect NTC 195 30131 0,006472 1,532183 127,2694 
    348 28868 0,012055 0,851575 408,6547 
    103 26796 0,003844 1,203277 85,59959 
    141 27551 0,005118 1,058363 133,2247 
  OE 76 27469 0,002767 1,331909 57,06098 
    119 28639 0,004155 0,845062 140,8181 
    91 33438 0,002721 1,550094 58,70612 
    105 29144 0,003603 1,219559 86,09668 
Bgal only NTC 62 25152   0,565003   
    59 25024   1,838294   
    77 16981   1,701521   
    65 23148   1,65593   
  OE 70 20494   1,045337   
    63 22192   1,263522   
    66 20126   1,545209   
    73 17795   1,050221   
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F-test – Figure 21 
 
T-test – Figure 21 
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13.5 Transfection 4 
Data – Figure 22 
    Luc Renilla Luc/renilla Protein conc. Protein conc. LUC/protein 
Perfect Neg 1300 307 4,234528 1,577774 1,577774 823,9455 
    761 263 2,893536 0,859716 0,859716 885,176 
    672 235 2,859574 1,195136 1,195136 562,2793 
    165 187 0,882353 0,897166 0,897166 183,9125 
  Pos 162 253 0,640316 0,835292 0,835292 193,9441 
    310 477 0,649895 1,296087 1,296087 239,1815 
    432 460 0,93913 0,851575 0,851575 507,2955 
    508 420 1,209524 1,344935 1,344935 377,7136 
Mut Neg 46264 1318 35,10167 1,261894 1,261894 36662,36 
    32776 1046 31,33461 0,9395 0,9395 34886,63 
    26663 850 31,36824 1,315626 1,315626 20266,4 
    21319 627 34,00159 0,88414 0,88414 24112,7 
  Pos 59841 2110 28,36066 0,766906 0,766906 78029,15 
    56449 1648 34,25303 0,877627 0,877627 64320,05 
    43617 1366 31,93045 1,1625 1,1625 37520 
    38759 1313 29,51942 0,954155 0,954155 40621,3 
PDHx Neg 1157 535 2,162617 0,875999 0,875999 1320,779 
    963 423 2,276596 1,545209 1,545209 623,2166 
    997 453 2,200883 0,91182 0,91182 1093,418 
    830 361 2,299169 0,825523 0,825523 1005,424 
  Pos 873 767 1,138201 1,219559 1,219559 715,8324 
    1095 844 1,297393 0,823895 0,823895 1329,054 
    846 791 1,069532 1,240727 1,240727 681,8586 
    793 790 1,003797 1,257009 1,257009 630,8626 
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F-test – Figure 22 
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T-test – Figure 22 
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13.6 Raw FF luciferase data 
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Figure III 
 
Figure IV  
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13.7 Standard curves for protein measurements 
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13.8 BLAST align of pCMV-LacZ and miR-29a 
The pCMV-LacZ has a predicted target site for miR-29a. The six bases GGTGCT at position 3143-3148 is 
reverse complimentary to miR-29a seed sequence: 
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14 Abbreviations 
Bp   Basepair 
E1   Pyruvate dehydrogenase 
E2   Dihydrolipoyl acyltransferase 
E3   Dhydrolipoyl dehydrogenase 
E3BP   E3 binding protein 
FF   Firefly 
GSIS   Glucose stimulated insulin secretion 
LB   Lysogeny broth 
MUT   Mutant 
MCT1   monocarboxylate transporter1 
Nt   Nucleotides 
NTC   Negative target construct 
OE   Over-expressed 
PCR   Polymerase Chain Reaction 
PDH   Pyruvate degydrogenase 
PDC   Pyruvate dehydrogenase complex 
PDP   Pyruvate dehydrogenase phosphatase 
PDK   Pyruvate degydrogenase kinase 
RR   Renilla Reniformis 
Stx-1a   Syntaxin-1a 
TCA   Tricarboxylic acid 
TPP   thiamine pyrophosphate 
UTR   Untranslated region (referring to the 3’UTR at all times)  
WT   Wild type 
 
 
 
 
